<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PeerJ</journal-id><journal-id journal-id-type="iso-abbrev">PeerJ</journal-id><journal-id journal-id-type="publisher-id">peerj</journal-id><journal-title-group><journal-title>PeerJ</journal-title></journal-title-group><issn pub-type="epub">2167-8359</issn><publisher><publisher-name>PeerJ Inc.</publisher-name><publisher-loc>San Diego, USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC12101446</article-id><article-id pub-id-type="publisher-id">19337</article-id><article-id pub-id-type="doi">10.7717/peerj.19337</article-id><article-categories><subj-group subj-group-type="heading"><subject>Bioinformatics</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Gastroenterology and Hepatology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology</subject></subj-group><subj-group subj-group-type="heading"><subject>Oncology</subject></subj-group></article-categories><title-group><article-title>Bulk and single-cell RNA sequencing identify prognostic signatures related to FGFBP2<sup>+</sup> NK cell in hepatocellular carcinoma</article-title></title-group><contrib-group><contrib id="author-1" contrib-type="author" equal-contrib="yes"><name><surname>Wu</surname><given-names>Yinbing</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-2" contrib-type="author" equal-contrib="yes"><name><surname>Peng</surname><given-names>Huanjun</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-3" contrib-type="author"><name><surname>Chen</surname><given-names>Guangkang</given-names></name><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-4" contrib-type="author" corresp="yes"><name><surname>Tu</surname><given-names>Yinuo</given-names></name><email>tuyinuo123@126.com</email><xref rid="aff-1" ref-type="aff">1</xref></contrib><contrib id="author-5" contrib-type="author" corresp="yes"><name><surname>Yu</surname><given-names>Xinpei</given-names></name><email>yxinpei@gzhmu.edu.cn</email><xref rid="aff-2" ref-type="aff">2</xref></contrib><aff id="aff-1"><label>1</label><institution>Department of Hepatobiliary Surgery, Affiliated Cancer Hospital &#x00026; Institute of Guangzhou Medical University</institution>, <city>Guangzhou</city>, <country>China</country></aff><aff id="aff-2"><label>2</label><institution>Department of Oncology, Affiliated Cancer Hospital &#x00026; Institute of Guangzhou Medical University</institution>, <city> Guangzhou</city>, <country>China</country></aff></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Guan</surname><given-names>Fanglin</given-names></name></contrib></contrib-group><pub-date pub-type="epub"><day>20</day><month>5</month><year iso-8601-date="2025">2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>13</volume><elocation-id>e19337</elocation-id><history><date date-type="received" iso-8601-date="2025-01-07"><day>7</day><month>1</month><year iso-8601-date="2025">2025</year></date><date date-type="accepted" iso-8601-date="2025-03-27"><day>27</day><month>3</month><year iso-8601-date="2025">2025</year></date></history><permissions><copyright-statement>&#x000a9;2025 Wu et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Wu et al.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.</license-p></license></permissions><self-uri xlink:href="https://peerj.com/articles/19337"/><abstract><sec><title>Background</title><p>Hepatocellular carcinoma (HCC) is a highly aggressive malignancy. As a specific immune cell subpopulation, FGFBP2<sup>+</sup> NK cells play a crucial part in immune surveillance of HCC progression. This study set out to identify prognostic signature related to FGFBP2<sup>+</sup> NK cell in HCC.</p></sec><sec><title>Methods</title><p>Bulk and scRNA-seq data were derived from the public databases. The single cell atlas of HCC and heterogeneity of natural killer (NK) cells were delineated by &#x0201c;Seurat&#x0201d; package. Pseudo-time trajectory of FGFBP2<sup>+</sup> NK cell was constructed by &#x0201c;Monocle2&#x0201d; package. Cell-cell interactions were analyzed by &#x0201c;CellChat&#x0201d; package. Prognostic signature was screened to develop a RiskScore model, and the prediction robustness was verified. Immune cell infiltration and immunotherapy response were assessed between different risk groups. Drug sensitivity was predicted by &#x0201c;oncoPredict&#x0201d; package. The expressions of the prognosis gene signature were detected by <italic toggle="yes">in vitro</italic> test utilizing HCC cells. The effects of key genes on the proliferative, migratory and invasive capacity of HCC cells were assessed by EdU assay, wound healing and Transwell assay.</p></sec><sec><title>Results</title><p>The proportion of NK cell in HCC samples was markedly decreased than that in healthy samples. NK cell was further divided into three cell subpopulations, and FGFBP2<sup>+</sup> NK cell was associated with the prognosis of HCC patients. Pseudo-time trajectory analysis of FGFBP2<sup>+</sup> NK cell revealed two differential expression gene clusters. FGFBP2<sup>+</sup> NK cell exhibited extensive intercellular communication in HCC. Further, eight prognostic signatures were identified, including six &#x0201c;risk&#x0201d; genes (<italic toggle="yes">UBE2F</italic>, <italic toggle="yes">AHSA1</italic>, <italic toggle="yes">PTP4A2</italic>, <italic toggle="yes">CDKN2D</italic>, <italic toggle="yes">FTL</italic>, <italic toggle="yes">RGS2</italic>) and two &#x0201c;protective&#x0201d; genes (<italic toggle="yes">KLF2</italic>, <italic toggle="yes">GZMH</italic>). RiskScore model was established with good prognostic prediction performance. In comparison to low-risk group, high-risk group had poorer prognosis, lower immune cell infiltration, and higher TIDE score. Moreover, 16 drugs showed significant correlation with RiskScore. Additionally, the expressions of <italic toggle="yes">GZMH</italic> was downregulated while <italic toggle="yes">FTL</italic>, <italic toggle="yes">PTP4A2</italic>, <italic toggle="yes">UBE2F</italic>, <italic toggle="yes">CDKN2D</italic>, <italic toggle="yes">RGS2</italic>, and <italic toggle="yes">AHSA1</italic> were up-regulated in HCC cells. <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> silencing could suppress the proliferation, migration and invasion abilities of HCC cells.</p></sec><sec><title>Conclusion</title><p>This study identified eight prognostic gene signatures related to FGFBP2<sup>+</sup> NK cell in HCC, which may serve as potential therapeutic targets for HCC.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Hepatocellular carcinoma</kwd><kwd>FGFBP2<sup>+</sup> NK cell</kwd><kwd>Prognostic signature</kwd><kwd>Tumor microenvironment</kwd><kwd>Immunotherapy</kwd><kwd>Bulk RNA sequencing</kwd><kwd>Single-cell RNA sequencing</kwd></kwd-group><funding-group><award-group id="fund-1"><funding-source>Science popularization special project of Department of Science and Technology of Guangdong Province</funding-source><award-id>2023A1414020055</award-id></award-group><funding-statement>This study was supported by Science popularization special project of Department of Science and Technology of Guangdong Province (2023A1414020055). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Hepatocellular carcinoma (HCC) accounts for 80&#x02013;90% of all primary liver cancer cases (<xref rid="ref-34" ref-type="bibr">Li, Liu &#x00026; Qin, 2022</xref>; <xref rid="ref-66" ref-type="bibr">Zhou et&#x000a0;al., 2024</xref>) and is the fifth most frequently diagnosed malignancy and third highest in carcinoma-relevant mortality around the world (<xref rid="ref-65" ref-type="bibr">Zhao et&#x000a0;al., 2019</xref>; <xref rid="ref-38" ref-type="bibr">Li et&#x000a0;al., 2024d</xref>; <xref rid="ref-48" ref-type="bibr">Sensi et&#x000a0;al., 2024</xref>). It is generally believed that the critical risk factors leading to HCC primarily comprise hepatitis B/C virus infection, non-alcoholic fatty liver, and excessive alcohol consumption (<xref rid="ref-54" ref-type="bibr">Wang et&#x000a0;al., 2021</xref>; <xref rid="ref-3" ref-type="bibr">Cao, Hu &#x00026; Tang, 2023</xref>). Owing to the lack of obvious clinical symptoms and effective intervention strategies, the treatment outcomes for HCC have constantly attracted much attention (<xref rid="ref-26" ref-type="bibr">Kong &#x00026; Yao, 2021</xref>). For the moment, the detection of HCC in clinical is widely dependent on the imaging approaches such as ultrasonography, computerized tomography, and magnetic resonance (<xref rid="ref-68" ref-type="bibr">Zhou et&#x000a0;al., 2020b</xref>), as well as tumor biomarkers (particularly <italic toggle="yes">&#x003b1;</italic>-fetoprotein) (<xref rid="ref-57" ref-type="bibr">Wu et&#x000a0;al., 2022</xref>). However, the specificity and sensitivity of these screening techniques are far from satisfactory. As a consequence, most patients with HCC have progressed into advanced stage when diagnosed (<xref rid="ref-12" ref-type="bibr">Du et&#x000a0;al., 2021</xref>). In addition, despite chemotherapy, radiotherapy, targeted therapy, and immunotherapy have recently made remarkable progression (<xref rid="ref-42" ref-type="bibr">Liu et&#x000a0;al., 2023</xref>), the prognostic outcomes of HCC remains disappointing due to the high recurrence and metastasis rate, with the 5-year survival probability &#x0003c;30% (<xref rid="ref-71" ref-type="bibr">Zhu et&#x000a0;al., 2023b</xref>). Therefore, it is essential to develop novel prognostic signatures and offer promising therapeutic targets for HCC.</p><p>Researches have manifested that the prognosis of HCC patients is usually affected by the complicated tumor microenvironment (TME) (<xref rid="ref-72" ref-type="bibr">Zhu et&#x000a0;al., 2023a</xref>). In recent years, immunotherapy such as immune checkpoint inhibitors (ICIs) have shown great promise in the treatment of HCC (<xref rid="ref-21" ref-type="bibr">Huang et&#x000a0;al., 2021a</xref>). Whereas, one of the main barriers to effective immunotherapy is TME, which may contribute to immune tolerance and evasion in HCC (<xref rid="ref-45" ref-type="bibr">Luo et&#x000a0;al., 2022</xref>). Comprehensive excavation of the concealed information in TME is critical for understanding the pathogenesis of HCC and improving the patient prognosis (<xref rid="ref-56" ref-type="bibr">Wu et&#x000a0;al., 2024</xref>). Natural killer (NK) cell belongs to a member of innate immunity and is primarily found in human liver (<xref rid="ref-49" ref-type="bibr">Shin et&#x000a0;al., 2024</xref>). NK cell has strong cytotoxicity and immunosurveillance potential, exerting crucial roles in the first-line immune defense against HCC development (<xref rid="ref-17" ref-type="bibr">Hong et&#x000a0;al., 2022</xref>). The dysfunction of NK cell is considered to be a vital mechanism of immune escape in HCC (<xref rid="ref-52" ref-type="bibr">Sung &#x00026; Jang, 2018</xref>). It has been confirmed that compared with healthy individuals, the proportion of NK cell is markedly decreased in the patients with advanced HCC (<xref rid="ref-19" ref-type="bibr">Hosseinzadeh et&#x000a0;al., 2018</xref>). Immune cell therapy targeting NK cell has been emphatically recognized as the novel standard of care for advanced HCC (<xref rid="ref-18" ref-type="bibr">Hosseinzadeh et&#x000a0;al., 2019</xref>). Given the important immune regulation roles of NK cell in HCC, in-depth exploration of NK cell at molecular levels is likely to facilitate the discovery of new immunotherapy strategies.</p><p>The single-cell RNA sequencing (scRNA-seq) technique can reveal the heterogeneity and dynamic changes of specific cells in TME, while bulk RNA sequencing can provide the whole transcriptomic information of tumor samples (<xref rid="ref-6" ref-type="bibr">Chen et&#x000a0;al., 2024</xref>; <xref rid="ref-5" ref-type="bibr">Chen, Lin &#x00026; Luo, 2024</xref>). In this study, by integrating bulk and scRNA-seq analysis, we revealed the single cell atlas of HCC and the heterogeneity of NK cell. Further, we analyzed the correlation between NK cell (especially FGFBP2<sup>+</sup> NK cell) with the prognostic outcomes of HCC. A prognostic gene signature was then identified to construct RiskScore model, and the immune cell infiltration, as well as immunotherapy response was assessed between different risk groups. In addition, the impacts of prognostic signatures on HCC cell proliferation, migration and invasion were assessed by <italic toggle="yes">in vitro</italic> validation tests. We hope that this study could provide novel targets for immunotherapy in HCC, thereby enhancing treatment effectiveness and improving survival rates.</p></sec><sec><title>Material and methods</title><sec><title>Data collection and preprocessing</title><p>RNA sequencing data and clinical follow-up data of HCC samples were downloaded from The Cancer Genome Atlas (TCGA) database through Genomic Data Commons (GDC) Application Programming Interface (API). The ICGC-LIRI-JP dataset was collected from the HCCDB database. Then, after deleting samples that did not have clinical follow-up data or status, the Ensembl was transformed to a gene symbol, and the expression average value was taken for multiple gene symbols. Finally, 370 tumor samples and 50 control samples were acquired in TCGA-LIHC cohort, utilizing as the training set. The ICGC-LIRI-JP cohort contained 212 HCC samples, which was served as the validation set.</p><p>The scRNA-seq data of <uri xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162616">GSE162616</uri> dataset, including three HCC samples and three healthy liver samples, was derived from the Gene Expression Omnibus (GEO) database. For filtering the scRNA-seq data, each gene was set to be expressed in a minimum of three cells, and each cell expressed at least 200 genes. Then, the cells with nFeature_RNA &#x0003e;300, nCount_RNA &#x0003e;3,000, and mitochondrial gene expression percent.mito &#x0003c;25% were reserved. The NormalizeData function was applied for log conversion, and the FindVariableFeatures function was used to identify highly variable genes. Next, the ScaleData function was utilized to normalize the expression values of all genes, the RunPCA function was employed for principal component analysis (PCA), and the &#x0201c;harmony&#x0201d; R package was used to remove batch effects between different samples (<xref rid="ref-73" ref-type="bibr">Zulibiya et&#x000a0;al., 2023</xref>).</p></sec><sec><title>Cell clustering analysis</title><p>Cell clustering analysis of <uri xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162616">GSE162616</uri> dataset was conducted using the &#x0201c;Seurat&#x0201d; R package (<xref rid="ref-11" ref-type="bibr">Du et&#x000a0;al., 2024</xref>). Firstly, UMAP was conducted on the top 15 principal components (PCs) for dimensionality reduction. Then, the cells were clustered using the FindNeighbors and FindClusters functions, with cluster resolution of 0.1 for all cells and 0.3 for NK cells. Finally, cell types were annotated based on the marker genes provided by CellMarker2.0 database (<xref rid="ref-44" ref-type="bibr">Lu et&#x000a0;al., 2024</xref>).</p></sec><sec><title>Single-sample gene set enrichment analysis</title><p>The correlation between the prognosis of HCC and each type of NK cells was examined based on the single-sample gene set enrichment analysis (ssGSEA) score calculated utilizing &#x0201c;GSVA&#x0201d; R package for the tumor samples in TCGA-LIHC cohort (<xref rid="ref-55" ref-type="bibr">Wang et&#x000a0;al., 2023</xref>). The surv_cutpoint function was applied to find the optimal cut-off point, and HCC patients were divided into low- and high-score groups.</p></sec><sec><title>Pseudo-time trajectory analysis</title><p>In order to invesitgate the role of FGFBP2<sup>+</sup> NK cell in the progression of HCC, Monocle2 was used to construct pseudo-time trajectory (<xref rid="ref-53" ref-type="bibr">Tao et&#x000a0;al., 2024</xref>). The cds object was established by newCellDataSet function, and the genes expressed in less than 10 cells were filtered out. The differentially expressed genes (DEGs) between HCC samples and healthy samples were identified by differentialGeneTest function, and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was conducted on these DEGs using the &#x0201c;ClusterProlifer&#x0201d; R package (<xref rid="ref-64" ref-type="bibr">Zhang et&#x000a0;al., 2024</xref>). Subsequently, the reduceDimension function was employed for dimensionality reduction (max_components = 2, method = &#x0201c;DDRTree&#x0201d;), and the orderCells function was applied to order the cells and construct the pseudo-time trajectory of FGFBP2<sup>+</sup> NK cell.</p></sec><sec><title>Cellular communication analysis</title><p>The &#x0201c;CellChat&#x0201d; R package was employed to conduct cell&#x02013;cell interaction analysis in HCC (<xref rid="ref-39" ref-type="bibr">Lian et&#x000a0;al., 2024</xref>). The number of interactions and interaction weights/strength was analyzed, as well as the key ligand&#x02013;receptor pairs between FGFBP2<sup>+</sup> NK cell and other cell subpopulations were visualized by a bubble plot.</p></sec><sec><title>Establishment and verification of RiskScore model</title><p>Univariate Cox regression analysis (<italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) was performed on the marker genes of FGFBP2<sup>+</sup> NK cell. The number of genes in the model was reduced by LASSO Cox regression analysis was conducted using the &#x0201c;glmnet&#x0201d; R package (<xref rid="ref-63" ref-type="bibr">Zeng &#x00026; Chen, 2024</xref>). By 10-fold cross validation, we selected the optimal lambda value as the result of LASSO regression for subsequent analysis. Further, stepwise regression analysis was performed, and the prognostic gene signature related to FGFBP2<sup>+</sup> NK cell in HCC was identified to establish RiskScore model. The RiskScore of each patient in TCGA-LIHC cohort was obtained according to the following formula (<xref rid="ref-30" ref-type="bibr">Li et&#x000a0;al., 2024a</xref>): <disp-formula id="NONUM-d2e465">
<alternatives><graphic xlink:href="peerj-13-19337-e001.jpg" position="float"/><tex-math id="tex-NONUM-d2e465">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
\begin{eqnarray*}\text{RiskScore}=\sum \mathrm{\beta }\text{i*ExPi} \end{eqnarray*}\end{document}</tex-math><mml:math id="mml-NONUM-d2e465" overflow="scroll"><mml:mstyle displaystyle="true"><mml:mtext>RiskScore</mml:mtext><mml:mo>=</mml:mo><mml:mo mathsize="big" movablelimits="false"> &#x02211;</mml:mo><mml:mi mathvariant="normal">&#x003b2;</mml:mi><mml:mtext>i*ExPi</mml:mtext></mml:mstyle></mml:math></alternatives>
</disp-formula>
</p><p>&#x003b2; is the coefficient of gene in Cox regression model, and i is the gene expression.</p><p><italic toggle="yes">Z</italic>-score was utilized for standardization, and based on the threshold of RiskScore = 0, high- and low-risk groups were classified. To evaluate the prognostic prediction performance of RiskScore model, receiver operating characteristic (ROC) analysis was conducted using the &#x0201c;timeROC&#x0201d; R package (<xref rid="ref-40" ref-type="bibr">Lin et&#x000a0;al., 2023</xref>). Additionally, the robustness of RiskScore model was validated in the ICGC-LIRI-JP cohort.</p></sec><sec><title>Immune cell infiltration and immunotherapy response analysis</title><p>Immune cell infiltration was assessed between high- and low-risk groups in TCGA-LIHC cohort. StromalScore, ImmuneScore, and ESTIMATEScore were calculated by the &#x0201c;estimate&#x0201d; R package (<xref rid="ref-10" ref-type="bibr">Dong et&#x000a0;al., 2023</xref>). Tumor Immune Estimation Resource (TIMER) was applied to assess the infiltration of six immune cells (<xref rid="ref-58" ref-type="bibr">Xiao et&#x000a0;al., 2020</xref>). Microenvironment cell populations-counter (MCP-counter) algorithm was utilized to assess the infiltration of 10 immune cells (<xref rid="ref-7" ref-type="bibr">Chen et&#x000a0;al., 2022</xref>).</p><p>The response of different risk groups to immunotherapy was predicted by TIDE algorithm (<xref rid="ref-32" ref-type="bibr">Li et&#x000a0;al., 2024b</xref>). Exclusion, Dysfunction, and TIDE scores of different risk groups were calculated in TCGA-LIHC cohort. Moreover, we analyzed the relationship of RiskScore and 9 immune checkpoint genes.</p></sec><sec><title>Correlation analysis between RiskScore and drug sensitivity</title><p>The IC<sub>50</sub> values of drugs for HCC patients in TCGA-LIHC cohort were predicted using the &#x0201c;oncoPredict&#x0201d; R package (<xref rid="ref-46" ref-type="bibr">Maeser, Gruener &#x00026; Huang, 2021</xref>). Then, the association between RiskScore and drug sensitivity was analyzed (<italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05 and |cor| &#x0003e;&#x000a0;0.3).</p></sec><sec><title>Cell culture and transfection</title><p>Human hepatic astrocyte cell line LX-2 (BNCC337957) and HCC cell line Huh7 (BNCC337690) were acquired from the BeNa Culture Collection (BNCC) Biotechnology Co. (Beijing, China). Then, LX-2 and Huh7 cell lines were separately cultivated in RPMI-1640 (BNCC338360) and DMEM (BNCC363314) contained 10% fetal bovine serum (FBS), and were all incubated in the condition of 5% CO<sub>2</sub> and 37&#x000a0;&#x000b0;C. Hereafter, according to the protocol of Lipofectamine 2000 (Invitrogen, Waltham, MA, USA), Huh7 cells were transfected with the small interfering (si) RNA of <italic toggle="yes">FTL</italic> (si-<italic toggle="yes">FTL</italic>: 5&#x02032;-TCCCAGATTCGTCAGAATTATTC-3&#x02032;, Sangon, China), (si) RNA of <italic toggle="yes">PTP4A2</italic> (si-<italic toggle="yes">PTP4A2</italic>: 5&#x02032;-GAGGTTCTATGTGCCATAATTAA-3&#x02032;, Sangon, China) and negative control (si-NC). We have performed short tandem repeat (STR) identification on the cells, and the mycoplasma detection results turned out to be negative.</p></sec><sec><title>Quantitative real-time PCR</title><p>Total RNA of LX-2 and Huh7 cells were acquired employing the Trizol reagent (B610409, Sangon, China). Then, the complementary DNA (cDNA) was synthesized through reverse transcription applying the RevertAid First Strand cDNA Synthesis Kit (B300538, Sangon, China). Thereafter, quantitative real-time PCR (qRT-PCR) amplification was performed using the SYBR Green (B110031, Sangon, China) on the basis of manufacturer&#x02019;s instructions. The qPCR conditions were: 94&#x000a0;&#x000b0;C for 30 s first, then 40 cycles of 94&#x000a0;&#x000b0;C for 5 s and 60&#x000a0;&#x000b0;C for 30 s. The primer pairs of this study were shown in <xref rid="supp-3" ref-type="supplementary-material">Table S1</xref>. <italic toggle="yes">GAPDH</italic> was utilized as an internal control to normalize the relative mRNA expressions of each gene by 2<sup>&#x02212;&#x00394;&#x00394;CT</sup> method (<xref rid="ref-60" ref-type="bibr">Xu et&#x000a0;al., 2020b</xref>).</p></sec><sec><title>Proliferation assay</title><p>Huh-7 cells that had been transfected were maintained for 48&#x000a0;h until they reached the logarithmic growth phase, after which they were moved into 96-well plates. The EdU Cell Proliferation Assay Kit (RiboBio, Guangzhou, China) was utilized to evaluate cell proliferation. In accordance with the established protocol, the cells underwent staining, followed by examination and imaging using a fluorescence microscope (Nikon, Toyko, Japan). EdU-positive cell counts were conducted using ImageJ software.</p></sec><sec><title>Wound healing assay</title><p>The effect of <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> silencing on the migration of HCC cells Huh7 was measured by wound healing assay (<xref rid="ref-50" ref-type="bibr">Song et&#x000a0;al., 2021</xref>). The transfected Huh7 cells (1&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup>) were inoculated into a 6-well plate and grown overnight. Afterwards, the wound was created using a sterile 20 &#x000b5;L pipette tip and Huh7 cells were sustainably cultured in serum-free medium for 48&#x000a0;h. Finally, the pictures of wound areas at 0&#x000a0;hour (h) and 48&#x000a0;h were obtained under a microscope (ECLIPSE Ei, Nikon, Tokyo, Japan), and the wound closure (%) of Huh7 cells was estimated with the ImageJ2 software.</p></sec><sec><title>Transwell assay</title><p>Transwell assay was conducted to examine the influence of <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> silencing on the invasion of HCC cells Huh7 (<xref rid="ref-20" ref-type="bibr">Huang et&#x000a0;al., 2021b</xref>). The diluted Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) was pre-coated into the Transwell chamber (8.0 &#x000b5;m, Corning, Corning, NY, USA). Next, the transfected Huh7 cells (1 &#x000d7; 10<sup>5</sup>) were starved in the upper chamber encompassing 200 &#x000b5;L non-serum medium. 500 &#x000b5;L DMEM containing 10% FBS was filled into the lower chamber. After 48&#x000a0;h of incubation, the invaded Huh7 cells were fixed by 4% paraformaldehyde (YTB1299, bjbalb, Beijing, China) and dyed by 0.1% crystal violet (YT913, bjbalb, Beijing, China). Further, the number of invaded Huh7 cells was counted under the same microscope as above.</p></sec><sec><title>Statistical analysis</title><p>The bioinformatic analysis was conducted using R programing language (version 4.1.0). The differences between different groups were compared by the Wilcoxon rank-sum test. Kaplan&#x02013;Meier (K-M) analysis of overall survival (OS) was conducted by log-rank test. The Spearman method was utilized for correlation analysis. All experimental data of independent triplicates were expressed as mean&#x000a0;&#x000b1;&#x000a0;standard deviation,, and statistical analysis was carried out by GraphPad Prism8.0. For data that did not conform to a normal distribution, non-parametric tests such as the Mann&#x02013;Whitney <italic toggle="yes">U</italic> test or Kruskal-Wallis test were applied. <italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05 signified statistical significance.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Single-cell atlas of HCC revealed the reduction proportion of NK cell</title><p>The scRNA-seq data of <uri xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162616">GSE162616</uri> dataset was analyzed to delineate the single-cell atlas of HCC. After cell filtration, standardization, dimensionality reduction, and clustering, a total of 47,550 cells were obtained and divided into 11 cell clusters (<xref rid="supp-1" ref-type="supplementary-material">Fig. S1</xref>). Using the marker genes, these cells were further annotated as seven cell types (<xref rid="fig-1" ref-type="fig">Fig. 1A</xref>), comprising NK cell (<italic toggle="yes">GZMB</italic>, <italic toggle="yes">GZMH</italic>, <italic toggle="yes">FGFBP2</italic>, <italic toggle="yes">GNLY</italic>, <italic toggle="yes">CD160</italic>), T cell (<italic toggle="yes">CD2</italic>, <italic toggle="yes">CD3D</italic>, <italic toggle="yes">CD3E</italic>, <italic toggle="yes">IL7R</italic>), macrophage (<italic toggle="yes">AIF1</italic>, <italic toggle="yes">MS4A7</italic>, <italic toggle="yes">LYZ</italic>), plasma cell (<italic toggle="yes">DERL3</italic>, <italic toggle="yes">IGHG1</italic>, <italic toggle="yes">MZB1</italic>), CD8<sup>+</sup> T cell (<italic toggle="yes">MKI67</italic>, <italic toggle="yes">STMN1</italic>), B cell (<italic toggle="yes">CD79A</italic>, <italic toggle="yes">MS4A1</italic>), and hepatocyte (<italic toggle="yes">ALB</italic>, <italic toggle="yes">APOA1</italic>, <italic toggle="yes">KRT18</italic>) (<xref rid="fig-1" ref-type="fig">Fig.&#x000a0;1B</xref>). Additionally, the proportion of each cell type in different samples was analyzed, showing that the number of NK cell in HCC samples was markedly decreased compared with healthy samples (<xref rid="fig-1" ref-type="fig">Figs.&#x000a0;1C</xref> and <xref rid="fig-1" ref-type="fig">1D</xref>). These results indicated that the proliferation and activity of NK cell may be inhibited in HCC microenvironment.</p><fig position="float" id="fig-1"><object-id pub-id-type="doi">10.7717/peerj.19337/fig-1</object-id><label>Figure 1</label><caption><title>Single-cell atlas of hepatocellular carcinoma (HCC).</title><p>(A) UMAP plot of cell subpopulations after annotation; (B) Expression level of marker genes in each cell type; (C&#x02013;D) Proportion of each cell type in different samples.</p></caption><graphic xlink:href="peerj-13-19337-g001" position="float"/></fig></sec><sec><title>FGFBP2<sup>+</sup> NK cell was associated with the prognosis of HCC patients</title><p>NK cell as an important immune cell can recognize and kill tumor cells. Hence, we extracted the NK cell from HCC tissues for re-clustering, obtaining three cell subpopulations (<xref rid="fig-2" ref-type="fig">Fig. 2A</xref>). The top20 highly expressed genes in each NK cell subpopulation were displayed by a heatmap (<xref rid="fig-2" ref-type="fig">Fig. 2B</xref>). Using the marker genes, these cell subpopulations were annotated as FGFBP2<sup>+</sup> NK cell (<italic toggle="yes">FGFBP2</italic>, <italic toggle="yes">FCGR3A</italic>, <italic toggle="yes">GZMB</italic>, <italic toggle="yes">GZMH</italic>), CD160<sup>+</sup> NK cell (<italic toggle="yes">GZMK</italic>, <italic toggle="yes">CD160</italic>), and IL7R<sup>+</sup> NK cell (<italic toggle="yes">IL7R</italic>, <italic toggle="yes">SELL</italic>, <italic toggle="yes">LMNA</italic>, <italic toggle="yes">CD44</italic>) (<xref rid="fig-2" ref-type="fig">Fig. 2C</xref>). Compared with healthy samples, the proportion of FGFBP2<sup>+</sup> NK cell and IL7R<sup>+</sup> NK cell was elevated while CD160<sup>+</sup> NK cell was decreased in HCC samples (<xref rid="fig-2" ref-type="fig">Fig. 2D</xref>). Furthermore, K-M survival curve suggested that FGFBP2<sup>+</sup> NK cell exhibited an association with the prognosis of HCC patients (<italic toggle="yes">p</italic> =0.047), with higher survival probability in high ssGSEA score group in comparison to the low ssGSEA score group (<xref rid="fig-2" ref-type="fig">Fig. 2E</xref>). Whereas, CD160<sup>+</sup> NK cell (<italic toggle="yes">p</italic> =0.082) and IL7R<sup>+</sup> NK cell (<italic toggle="yes">p</italic> =0.1) was not closely related to the prognosis of HCC patients (<xref rid="supp-2" ref-type="supplementary-material">Fig. S2</xref>).</p><fig position="float" id="fig-2"><object-id pub-id-type="doi">10.7717/peerj.19337/fig-2</object-id><label>Figure 2</label><caption><title>Analysis of natural killer (NK) cell heterogeneity.</title><p>(A) UMAP plot of NK cell subpopulations after annotation; (B) Highly expressed genes in each NK cell type; (C) Marker genes in each NK cell type; (D) Proportion of each NK cell type in different samples; (E) Kaplan&#x02013;Meier (K&#x02013;M) survival curve of ssGSEA score of FGFBP2<sup>+</sup> NK cell in TCGA-LIHC cohort.</p></caption><graphic xlink:href="peerj-13-19337-g002" position="float"/></fig></sec><sec><title>Pseudo-time trajectory of FGFBP2<sup>+</sup> NK cell from normal to HCC was constructed</title><p>For further exploring the role of FGFBP2<sup>+</sup> NK cell in HCC progression, the pseudo-time trajectory of FGFBP2<sup>+</sup> NK cell from normal to HCC was constructed by Monocle2, and the branch with more healthy samples was set as the starting point, and the branch with more HCC samples was set as the ending point (<xref rid="fig-3" ref-type="fig">Figs. 3A</xref> and <xref rid="fig-3" ref-type="fig">3B</xref>). Moreover, DEGs analysis between HCC samples and healthy samples revealed two differential expression gene clusters, and the gene expression in Cluster1 was gradually up-regulated with the increase of pseudo-time (<xref rid="fig-3" ref-type="fig">Fig. 3C</xref>). KEGG enrichment analysis demonstrated that the DEGs in Cluster1 were primarily involved in the endocytosis, protein processing in nuclear factor (NF)-kappa B signaling pathway, endoplasmic reticulum, apoptosis, antigen processing and presentation, NK cell mediated cytotoxicity (<xref rid="fig-3" ref-type="fig">Fig. 3D</xref>). These pathways might play a crucial role in the process of FGFBP2<sup>+</sup> NK cells transitioning from the normal state to be involved in HCC.</p><fig position="float" id="fig-3"><object-id pub-id-type="doi">10.7717/peerj.19337/fig-3</object-id><label>Figure 3</label><caption><title>Construction of pseudo-time trajectory of FGFBP2<sup>+</sup> NK cell.</title><p>(A&#x02013;B) Differentiation trajectory of FGFBP2<sup>+</sup> NK cell from normal to HCC; (C) Heatmap of DEGs between HCC samples and healthy samples; (D) KEGG enrichment pathways of DEGs in Cluster1.</p></caption><graphic xlink:href="peerj-13-19337-g003" position="float"/></fig></sec><sec><title>FGFBP2<sup>+</sup> NK cell exhibited extensive intercellular communication in HCC</title><p>Cellular communication analysis was performed to explore the potential interactions between different cell types in HCC. It was observed that the number and strength of ligand&#x02013;receptor interactions was complicated (<xref rid="fig-4" ref-type="fig">Fig. 4A</xref>). FGFBP2<sup>+</sup> NK cell as signal sender showed extensive communication with Macrophage, B cell, IL7R<sup>+</sup> NK cell, T cell, CD160<sup>+</sup> NK cell, and CD8<sup>+</sup> T cell (<xref rid="fig-4" ref-type="fig">Fig. 4B</xref>). By extracting the critical ligand&#x02013;receptor pairs, we found that FGFBP2<sup>+</sup> NK cell communicated with other cell subpopulations <italic toggle="yes">via</italic> tumor necrosis factor (TNF)-TNFRSF1B and macrophage migration inhibitory factor (MIF)-(CD74+CD44) (<xref rid="fig-4" ref-type="fig">Fig. 4C</xref>), while other cell subpopulations communicated with FGFBP2<sup>+</sup> NK cell <italic toggle="yes">via</italic> TNFSF14-TNFRSF14 and MIF-(CD74+CXCR4) (<xref rid="fig-4" ref-type="fig">Fig. 4D</xref>).</p><fig position="float" id="fig-4"><object-id pub-id-type="doi">10.7717/peerj.19337/fig-4</object-id><label>Figure 4</label><caption><title>Cellular communication analysis in HCC.</title><p>(A) Cell&#x02013;cell interactions network between different cell subpopulations; (B) Cell communication of FGFBP2<sup>+</sup> NK cell as a signal sender; (C) Key ligand&#x02013;receptor pairs of FGFBP2<sup>+</sup> NK cell acting on other cell subpopulations; (D) Key ligand&#x02013;receptor pairs of other cell subpopulations acting on FGFBP2<sup>+</sup> NK cell.</p></caption><graphic xlink:href="peerj-13-19337-g004" position="float"/></fig></sec><sec><title>RiskScore model was constructed and verified based on 8-genes prognostic signature</title><p>Firstly, the marker genes in FGFBP2<sup>+</sup> NK cell were subjected to univariate Cox regression analysis (<italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05). LASSO and stepwise regression analysis was further performed to reduce the gene number, and the model was optimal when the lambda was 0.0286 (<xref rid="fig-5" ref-type="fig">Figs.&#x000a0;5A</xref> and <xref rid="fig-5" ref-type="fig">5B</xref>). Then, eight prognostic signatures related to FGFBP2<sup>+</sup> NK cell in HCC were identified, including six &#x0201c;risk&#x0201d; genes (<italic toggle="yes">UBE2F</italic>, <italic toggle="yes">AHSA1</italic>, <italic toggle="yes">PTP4A2</italic>, <italic toggle="yes">CDKN2D</italic>, <italic toggle="yes">FTL</italic>, <italic toggle="yes">RGS2</italic>) and two &#x0201c;protective&#x0201d; genes (<italic toggle="yes">KLF2</italic>, <italic toggle="yes">GZMH</italic>) (<xref rid="fig-5" ref-type="fig">Fig. 5C</xref>). Next, we established a RiskScore model of &#x0201c;RiskScore = &#x02212;0.352*GZMH&#x02212;0.303*KLF2+0.153*FTL+0.312*PTP4A2+0.442*UBE2F+ 0.234*CDKN2D+0.141*RGS2+0.427*AHSA1&#x0201d;.</p><fig position="float" id="fig-5"><object-id pub-id-type="doi">10.7717/peerj.19337/fig-5</object-id><label>Figure 5</label><caption><title>Establishment and verification of RiskScore model.</title><p>(A) Coefficients of each independent variable; (B) Confidence interval for each lambda; (C) Prognostic gene signatures in RiskScore model; (D) RiskScore, survival status, and signature expression level in TCGA-LIHC cohort; (E) ROC analysis and K-M survival curves in TCGA-LIHC cohort; (F) RiskScore, survival Status, and signature expression level in ICGC-LIRI-JP cohort; (G) ROC analysis and K-M survival curves in ICGC-LIRI-JP cohort.</p></caption><graphic xlink:href="peerj-13-19337-g005" position="float"/></fig><p>Furthermore, according to the threshold of RiskScore = 0, all samples in TCGA-LIHC cohort were separated into high- and low-risk groups (<xref rid="fig-5" ref-type="fig">Fig. 5D</xref>). The performance of RiskScore model was evaluated by the area under ROC curve (AUC). It was showed that 1-, 3-, 5-years AUC values of the RiskScore model were 0.78, 0.77, 0.76 (<xref rid="fig-5" ref-type="fig">Fig. 5E</xref>), which manifested that the RiskScore model exhibited good prognostic prediction performance. K-M curve analysis suggested that the OS rate of high-risk group was lower (<xref rid="fig-5" ref-type="fig">Fig. 5E</xref>), showing that HCC patients with high RiskScore may have a poor prognosis. The robustness of RiskScore model was verified in ICGC-LIRI-JP cohort, and the results of which were similar to the TCGA-LIHC cohort (<xref rid="fig-5" ref-type="fig">Figs. 5F</xref> and <xref rid="fig-5" ref-type="fig">5G</xref>). These outcomes demonstrated the reliability of the RiskScore model in the prognostic predicting of HCC.</p></sec><sec><title>RiskScore model exhibited potential in predicting immunotherapy response for HCC</title><p>We first elucidated the association between RiskScore and immune cell infiltration. ESTIMATE algorithm results showed that compared to low-risk group, high-risk group had lower StromalScore, ImmuneScore, and ESTIMATEScore (<xref rid="fig-6" ref-type="fig">Fig. 6A</xref>). Based on the TIMER database, the infiltration levels of neutrophil, B cell, macrophage, and dendritic cell (DC) in high-risk group were significantly higher, while CD8 T cell was notably lower in comparison to the low-risk group (<xref rid="fig-6" ref-type="fig">Fig. 6B</xref>). MCP-counter algorithm suggested that the infiltration levels of CD8 T cell, cytotoxic lymphocytes, NK cell, and endothelial cell were markedly lower, yet monocytic lineage was higher in high-risk group (<xref rid="fig-6" ref-type="fig">Fig. 6C</xref>). In addition, the immunotherapy response between different risk groups was predicted in TCGA-LIHC cohort. In comparison to low-risk group, high-risk group exhibited higher exclusion score and TIDE score (<xref rid="fig-6" ref-type="fig">Fig. 6D</xref>), demonstrating that high-risk HCC patients may be less likely to benefit from taking immunotherapy. RiskScore was positively correlated with several immune checkpoint genes, including <italic toggle="yes">CD44</italic>, <italic toggle="yes">CD276</italic>, <italic toggle="yes">CD80</italic>, <italic toggle="yes">LGALS9</italic>, and <italic toggle="yes">CTLA4</italic> (<xref rid="fig-6" ref-type="fig">Fig. 6E</xref>), showing that HCC patients with higher RiskScore may be more possibly to experience immune escape. Furthermore, we examined the association between drug sensitivity and RiskScore, and screened 16 drugs (such as Doramapimod, Nutlin.3a, Selumetinib, Sepantronium bromide, Tozasertib) that showed significant correlation with RiskScore (<italic toggle="yes">p</italic> &#x0003c;&#x000a0;0.05 and &#x02014;cor&#x02014; &#x0003e;&#x000a0;0.3) (<xref rid="fig-6" ref-type="fig">Fig. 6F</xref>).</p><fig position="float" id="fig-6"><object-id pub-id-type="doi">10.7717/peerj.19337/fig-6</object-id><label>Figure 6</label><caption><title>Correlation analysis between immune cell infiltration, immunotherapy response and RiskScore.</title><p>(A) StromalScore, ImmuneScore, and ESTIMATEScore between different risk groups; (B) Infiltration levels of six immune cells assessed by TIMER website; (C) Infiltration levels of 10 immune cells calculated by MCP-counter algorithm; (D) Exclusion, Dysfunction, and TIDE scores in different risk groups; (E) Relationship between RiskScore and immune checkpoint genes; (F) Correlation between RiskScore and drugs IC50; **** indicates <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; *** indicates <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001; ** indicates <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01; * indicates <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05; ns indicates not significant.</p></caption><graphic xlink:href="peerj-13-19337-g006" position="float"/></fig></sec><sec><title><italic toggle="yes">In vitro</italic> HCC cell-based model to validate key genes</title><p>The qRT-PCR analysis demonstrated that in comparison to the human hepatic astrocyte cells LX-2, the relative mRNA expression levels of <italic toggle="yes">GZMH</italic> was remarkably lower, yet <italic toggle="yes">FTL</italic>, <italic toggle="yes">PTP4A2</italic>, <italic toggle="yes">UBE2F</italic>, <italic toggle="yes">CDKN2D</italic>, <italic toggle="yes">RGS2</italic>, and <italic toggle="yes">AHSA1</italic> were notably higher in HCC cells Huh7 (<xref rid="fig-7" ref-type="fig">Fig. 7A</xref>). Since the pro-carcinogenic role of <italic toggle="yes">FTL</italic> in HCC has been reported in related studies, and the functional mechanism of <italic toggle="yes">PTP4A2</italic> in HCC lacks systematic studies, we chose these two genes for <italic toggle="yes">in vitro</italic> functional experiments to further validate their roles in HCC cell migration, invasion and proliferation. Thereafter, we verified the knockdown efficiency of these two genes in Huh-7 cells (<xref rid="supp-3" ref-type="supplementary-material">Fig. S3</xref>). We observed a significant decrease in proliferation of HCC cell lines after silencing <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> (<xref rid="fig-7" ref-type="fig">Fig. 7B</xref>). In addition, wound healing assay displayed that <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> silencing could decrease the wound closure rate of Huh7 cells (<xref rid="fig-7" ref-type="fig">Fig. 7C</xref>). Transwell assay suggested that the number of invading Huh7 cells was reduced by the silencing of <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> (<xref rid="fig-7" ref-type="fig">Fig. 7D</xref>). Consequently, these results indicated the crucial involvement of <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> in HCC progression.</p><fig position="float" id="fig-7"><object-id pub-id-type="doi">10.7717/peerj.19337/fig-7</object-id><label>Figure 7</label><caption><title>Effects of <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> silencing on the migration and invasion abilities of HCC cells.</title><p>(A) Relative mRNA expression of eight prognostic gene signatures detected by qRT-PCR; (B) Effect of <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> silencing on the proliferation ability of HCC cells was evaluated by EdU assay; (C) Impact of <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> silencing on the migration capability of HCC cells assessed <italic toggle="yes">via</italic> Wound healing assay; (D) Effect of <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> silencing on the invasion ability of HCC cells evaluated <italic toggle="yes">via</italic> Transwell assay; **** denotes <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.0001; *** denotes <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.001; ** denotes <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.01; * denotes <italic toggle="yes">p</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></caption><graphic xlink:href="peerj-13-19337-g007" position="float"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Numerous studies have indicated that NK cell function crucially in the surveillance and control of HCC, and NK cell dysfunction or exhaustion is implicated in the pathogenesis of advanced HCC (<xref rid="ref-13" ref-type="bibr">Eresen et&#x000a0;al., 2024</xref>; <xref rid="ref-29" ref-type="bibr">Lee et&#x000a0;al., 2021b</xref>). The prognostic significance of NK cell in TME of HCC has been widely concerned, and NK cell is highly considered as a promising target for tumor immunotherapy (<xref rid="ref-61" ref-type="bibr">Yang et&#x000a0;al., 2023</xref>; <xref rid="ref-31" ref-type="bibr">Li et&#x000a0;al., 2023</xref>). In this study, we innovatively combined scRNA-seq and bulk RNA-seq analyses to systematically resolve the heterogeneity of FGFBP2<sup>+</sup> NK cells in HCC and its association with prognosis, and constructed a RiskScore model based on FGFBP2<sup>+</sup> NK cell-related genes, which provides a new molecular basis for prognostic assessment of HCC patients and immunotherapy response prediction. Compared with previous studies, this study not only revealed the role of FGFBP2<sup>+</sup> NK cells in the HCC microenvironment, but also explored the function of their related genes in HCC progression, revealing new potential targets for NK cell-targeted immunotherapy.</p><p><italic toggle="yes">FGFBP2</italic> served as the signature gene responsible for the cytotoxic killing function within NK cells (<xref rid="ref-36" ref-type="bibr">Li et&#x000a0;al., 2010</xref>). Some researchers have identified <italic toggle="yes">FGFBP2</italic> as a key gene involved in NK cell-mediated immune response in ankylosing spondylitis (<xref rid="ref-4" ref-type="bibr">Chen et&#x000a0;al., 2025</xref>). <xref rid="ref-9" ref-type="bibr">Cui et&#x000a0;al. (2024)</xref> identified two cell subpopulations in NK cells of HCC, including FGFBP2<sup>+</sup> NK cells and B3GNT7<sup>+</sup> NK cells. They suggested that the impairment of these functional anticancer cells is the potential cause of HCC. These studies suggest that the reduction of FGFBP2<sup>+</sup> NK cells may impair the cytotoxic activity of NK cells, which in turn affects the immune response and prognosis of HCC patients, suggesting that it is expected to be a potential target for HCC immunotherapy. In addition, the eight prognostic signatures related to FGFBP2<sup>+</sup> NK cell in HCC comprised six &#x0201c;risk&#x0201d; genes (<italic toggle="yes">UBE2F</italic>, <italic toggle="yes">AHSA1</italic>, <italic toggle="yes">PTP4A2</italic>, <italic toggle="yes">CDKN2D</italic>, <italic toggle="yes">FTL</italic>, and <italic toggle="yes">RGS2</italic>) and two &#x0201c;protective&#x0201d; genes (<italic toggle="yes">KLF2</italic>, and <italic toggle="yes">GZMH</italic>). <italic toggle="yes">In vitro</italic> assays showed that compared with the human hepatic astrocyte cells LX-2, the relative mRNA expressions of <italic toggle="yes">FTL</italic>, <italic toggle="yes">PTP4A2</italic>, <italic toggle="yes">UBE2F</italic>, <italic toggle="yes">CDKN2D</italic>, <italic toggle="yes">RGS2</italic>, and <italic toggle="yes">AHSA1</italic> were notably higher in HCC cells Huh7. <italic toggle="yes">UBE2F</italic>, a ubiquitin-conjugating enzyme, is usually over-expressed in many malignant tumors such as lung cancer, resulting in a low OS rate (<xref rid="ref-69" ref-type="bibr">Zhou et&#x000a0;al., 2020a</xref>). Targeting <italic toggle="yes">UBE2F</italic> might serve as an effective sensitizing strategy of chemo-/radiotherapy through triggering tumor cell apoptosis (<xref rid="ref-67" ref-type="bibr">Zhou et&#x000a0;al., 2023</xref>). <italic toggle="yes">AHSA1</italic>, principally implicated in the activity of ATPase activators, is observed the upregulation of <italic toggle="yes">AHSA1</italic> in HCC that is linked to clinical stage and worse outcomes of patients (<xref rid="ref-14" ref-type="bibr">Gao et&#x000a0;al., 2023</xref>). Cell-based assays have manifested that knockdown of <italic toggle="yes">AHSA1</italic> can inhibit the proliferation, migration, and invasion capabilities of HCC cells (<xref rid="ref-33" ref-type="bibr">Li &#x00026; Liu, 2022</xref>). <italic toggle="yes">PTP4A2</italic> belongs to a member of regenerating liver phosphatase family and can mediate cellular bioenergetics (<xref rid="ref-16" ref-type="bibr">Hardy et&#x000a0;al., 2023</xref>). <italic toggle="yes">PTP4A2</italic> is essential for vascular morphogenesis and angiogenesis (<xref rid="ref-47" ref-type="bibr">Poulet et&#x000a0;al., 2020</xref>), which has been deemed as a carcinogenic factor in majority of human cancers, such as nasopharyngeal carcinoma (<xref rid="ref-15" ref-type="bibr">Gao et&#x000a0;al., 2017</xref>) and glioblastoma (<xref rid="ref-8" ref-type="bibr">Chouleur et&#x000a0;al., 2024</xref>). <italic toggle="yes">CDKN2D</italic>, a cyclin-dependent kinase inhibitor, exerts crucial roles in regulating tumor growth (<xref rid="ref-70" ref-type="bibr">Zhu et&#x000a0;al., 2021</xref>). The abnormal expression of <italic toggle="yes">CDKN2D</italic> contributes to the uncontrolled proliferation of malignant cells including HCC (<xref rid="ref-28" ref-type="bibr">Lee et&#x000a0;al., 2021a</xref>). <italic toggle="yes">FTL</italic>, also known as ferritin light chain, has been recognized to be one of the regulators in early iron metabolism (<xref rid="ref-27" ref-type="bibr">Kuang et&#x000a0;al., 2023</xref>). Recent study of <xref rid="ref-25" ref-type="bibr">Ke et&#x000a0;al. (2022)</xref> demonstrated that <italic toggle="yes">FTL</italic> was closely relevant to HCC progression, and patients with low <italic toggle="yes">FTL</italic> expression had a remarkable survival advantage. Our current study indicated that <italic toggle="yes">FTL</italic> silencing could markedly restrain the migration and invasion capabilities of HCC cells. <italic toggle="yes">RGS2</italic>, belonging to a GTPase-activating protein, functions as a key regulator of G-protein signaling (<xref rid="ref-2" ref-type="bibr">Cacan, 2017</xref>). Abnormal expression of <italic toggle="yes">RGS2</italic> in different tumor types is significantly correlated with poor prognosis (<xref rid="ref-23" ref-type="bibr">Ihlow et&#x000a0;al., 2022</xref>). There are few reports of <italic toggle="yes">RGS2</italic> in HCC, deserving further exploration. <italic toggle="yes">KLF2</italic>, a transcription factor of Kr&#x000fc;ppel-like factor family, can impede the tumor cell movement mediated by TGF-&#x003b2; signaling in HCC (<xref rid="ref-37" ref-type="bibr">Li et&#x000a0;al., 2020</xref>). <xref rid="ref-41" ref-type="bibr">Lin et&#x000a0;al. (2019)</xref> observed that the expression of <italic toggle="yes">KLF2</italic> was markedly decreased in HCC tissues than in adjacent tissues. <italic toggle="yes">GZMH</italic>, <italic toggle="yes">i.e.</italic>, Granzyme H, exerts crucial roles in tumor killing mediated by T cell and NK cell, acting as a predictor for tumor immunotherapy (<xref rid="ref-35" ref-type="bibr">Li et&#x000a0;al., 2024c</xref>). High <italic toggle="yes">GZMH</italic> expression is indicative of a better prognosis in HCC (<xref rid="ref-24" ref-type="bibr">Jin et&#x000a0;al., 2024</xref>). Overall, these findings supported that the RiskScore model, constructed with eight prognostic signatures in this study, was reliable in the prognostic evaluation for patients with HCC. Meanwhile, these eight prognostic signatures may be regarded as promising therapeutic targets for HCC.</p><p>Furthermore, we found that the ImmuneScore in high-risk group was remarkably lower than that in low-risk group. The infiltration levels of B cell, neutrophil, macrophage, and monocytic lineage were observably higher while CD8 T cell, cytotoxic lymphocytes, NK cell, and endothelial cell were markedly lower in high-risk group than low-risk group. CD8 T cell plays an anti-tumor effect through releasing interferon-&#x003b3; and TNF cytokines (<xref rid="ref-22" ref-type="bibr">Huo, Wu &#x00026; Zang, 2021</xref>). Cytotoxic T lymphocytes exert crucial roles in anti-tumor immunity by recognizing and eliminating cancer cells (<xref rid="ref-1" ref-type="bibr">Akazawa et&#x000a0;al., 2019</xref>). NK cell has strong anti-tumor activity <italic toggle="yes">via</italic> producing cytotoxic and cytokine (<xref rid="ref-62" ref-type="bibr">Zecca et&#x000a0;al., 2020</xref>). This suggested that the infiltration characteristics of immune cells form an immunosuppressive microenvironment that may be closely correlated with a worse prognosis of HCC patients (<xref rid="ref-51" ref-type="bibr">Sun et&#x000a0;al., 2023</xref>). The immunotherapy response in different risk groups was further predicted by TIDE algorithm, and high-risk group showed a higher TIDE score than low-risk HCC patients, which indicated that HCC patients in high-risk group might benefit limitedly from ICIs treatment (<xref rid="ref-43" ref-type="bibr">Liu et&#x000a0;al., 2022</xref>). Moreover, the RiskScore exhibited positive correlation with several immune checkpoint genes, including <italic toggle="yes">CD44</italic>, <italic toggle="yes">CD276</italic>, <italic toggle="yes">CD80</italic>, <italic toggle="yes">LGALS9</italic>, and <italic toggle="yes">CTLA4</italic>, demonstrating that HCC patients with higher RiskScore may be more possibly to experience immune evasion (<xref rid="ref-59" ref-type="bibr">Xu et&#x000a0;al., 2020a</xref>). Hence, these immune checkpoint genes could be the targets for HCC immunotherapy. In addition, the correlation between RiskScore and drug sensitivity was analyzed, and 16 drugs (such as Doramapimod, Nutlin.3a, Selumetinib, Sepantronium bromide, and Tozasertib) were screened, which supplied some reference for drug selection of HCC patients.</p><p>Nevertheless, there are also some shortcomings of the current study. The RiskScore model was constructed based on eight gene signatures, which was identified entirely from the data of public databases. It is necessary to further validate with prospective clinical data. Moreover, the specific mechanism of the eight prognostic gene signatures in HCC has not yet been investigated. In the future, we will consider performing a large number of <italic toggle="yes">in vivo</italic> and <italic toggle="yes">in vitro</italic> experiments to verify our outcomes.</p></sec><sec><title>Conclusion</title><p>In summary, based on bulk and scRNA-seq analysis, this study revealed eight prognostic gene signatures related to FGFBP2<sup>+</sup> NK cell in HCC, which were utilized to create a RiskScore model. This model exhibited strong performance in assessing the prognostic outcomes and immunotherapy of HCC patients. 16 drugs were screened to be correlated with RiskScore. Additionally, <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> expression was upregulated in HCC cells, and their silencing significantly inhibited cell proliferation, migration, and invasive capacity. This study could provide promising therapeutic targets for HCC patients and also supply some reference for drug development.</p></sec><sec sec-type="supplementary-material" id="supplemental-information"><title>Supplemental Information</title><supplementary-material id="supp-1" position="float" content-type="local-data"><object-id pub-id-type="doi">10.7717/peerj.19337/supp-1</object-id><label>Supplemental Information 1</label><caption><title>UMAP plot of cell clusters in HCC before annotation</title></caption><media xlink:href="peerj-13-19337-s001.pdf"/></supplementary-material><supplementary-material id="supp-2" position="float" content-type="local-data"><object-id pub-id-type="doi">10.7717/peerj.19337/supp-2</object-id><label>Supplemental Information 2</label><caption><title>Kaplan&#x02013;Meier (K&#x02013;M) survival curves of ssGSEA score of CD160+ NK cell and IL7R+ NK cell in TCGA-LIHC cohort</title></caption><media xlink:href="peerj-13-19337-s002.pdf"/></supplementary-material><supplementary-material id="supp-3" position="float" content-type="local-data"><object-id pub-id-type="doi">10.7717/peerj.19337/supp-3</object-id><label>Supplemental Information 3</label><caption><title>Validate the knockout efficiency of <italic toggle="yes">FTL</italic> and <italic toggle="yes">PTP4A2</italic> in Huh-7 cells based on qRT-PCR</title></caption><media xlink:href="peerj-13-19337-s003.pdf"/></supplementary-material><supplementary-material id="supp-4" position="float" content-type="local-data"><object-id pub-id-type="doi">10.7717/peerj.19337/supp-4</object-id><label>Supplemental Information 4</label><caption><title>Primer sequences used in qRT PCR</title></caption><media xlink:href="peerj-13-19337-s004.docx"/></supplementary-material><supplementary-material id="supp-5" position="float" content-type="local-data"><object-id pub-id-type="doi">10.7717/peerj.19337/supp-5</object-id><label>Supplemental Information 5</label><caption><title>MIQE checklist</title></caption><media xlink:href="peerj-13-19337-s005.xls"/></supplementary-material></sec></body><back><glossary content-type="abbreviations" id="glossary-1"><title>Abbreviations</title><def-list id="dl1"><def-item><term> API</term><def><p>Application Programming Interface</p></def></def-item><def-item><term> AUC</term><def><p>area under ROC curve</p></def></def-item><def-item><term> BNCC</term><def><p>BeNa Culture Collection</p></def></def-item><def-item><term> cDNA</term><def><p>complementary DNA</p></def></def-item><def-item><term> DC</term><def><p>dendritic cell</p></def></def-item><def-item><term> DEGs</term><def><p>differentially expressed genes</p></def></def-item><def-item><term> FBS</term><def><p>fetal bovine serum</p></def></def-item><def-item><term> GDC</term><def><p>Genomic Data Commons</p></def></def-item><def-item><term> GEO</term><def><p>Gene Expression Omnibus</p></def></def-item><def-item><term> HCC</term><def><p>hepatocellular carcinoma</p></def></def-item><def-item><term> IC50</term><def><p>half maximal inhibitory concentration</p></def></def-item><def-item><term> ICIs</term><def><p>immune checkpoint inhibitors</p></def></def-item><def-item><term> KEGG</term><def><p>Kyoto Encyclopedia of Genes and Genomes</p></def></def-item><def-item><term> K-M</term><def><p>Kaplan&#x02013;Meier</p></def></def-item><def-item><term> LASSO</term><def><p>least absolute shrinkage and selection operator</p></def></def-item><def-item><term> MCP-counter</term><def><p>microenvironment cell populations-counter</p></def></def-item><def-item><term> MIF</term><def><p>Macrophage migration inhibitory factor</p></def></def-item><def-item><term> NF</term><def><p>nuclear factor</p></def></def-item><def-item><term> NK</term><def><p>Natural killer</p></def></def-item><def-item><term> OS</term><def><p>overall survival</p></def></def-item><def-item><term> PCA</term><def><p>principal component analysis</p></def></def-item><def-item><term> qRT-PCR</term><def><p>quantitative real-time polymerase chain reaction</p></def></def-item><def-item><term> ROC</term><def><p>receiver operating characteristic</p></def></def-item><def-item><term> scRNA-seq</term><def><p>single-cell RNA sequencing</p></def></def-item><def-item><term> si</term><def><p>small interfering</p></def></def-item><def-item><term> ssGSEA</term><def><p>single-sample gene set enrichment analysis</p></def></def-item><def-item><term> TCGA</term><def><p>The Cancer Genome Atlas</p></def></def-item><def-item><term> TIDE</term><def><p>Tumor Immunity Dysfunction and Exclusion</p></def></def-item><def-item><term> TIMER</term><def><p>Tumor Immune Estimation Resource</p></def></def-item><def-item><term> TME</term><def><p>tumor microenvironment</p></def></def-item><def-item><term> TNF</term><def><p>tumor necrosis factor</p></def></def-item><def-item><term> UMAP</term><def><p>uniform manifold approximation and projection</p></def></def-item></def-list></glossary><sec sec-type="additional-information"><title>Additional Information and Declarations</title><fn-group content-type="competing-interests"><title>Competing Interests</title><fn id="conflict-1" fn-type="COI-statement"><p>The authors declare there are no competing interests.</p></fn></fn-group><fn-group content-type="author-contributions"><title>Author Contributions</title><fn id="contribution-1" fn-type="con"><p><xref rid="author-1" ref-type="contrib">Yinbing Wu</xref> conceived and designed the experiments, performed the experiments, analyzed the data, prepared figures and/or tables, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-2" fn-type="con"><p><xref rid="author-2" ref-type="contrib">Huanjun Peng</xref> conceived and designed the experiments, prepared figures and/or tables, and approved the final draft.</p></fn><fn id="contribution-3" fn-type="con"><p><xref rid="author-3" ref-type="contrib">Guangkang Chen</xref> performed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.</p></fn><fn id="contribution-4" fn-type="con"><p><xref rid="author-4" ref-type="contrib">Yinuo Tu</xref> performed the experiments, prepared figures and/or tables, and approved the final draft.</p></fn><fn id="contribution-5" fn-type="con"><p><xref rid="author-5" ref-type="contrib">Xinpei Yu</xref> conceived and designed the experiments, analyzed the data, authored or reviewed drafts of the article, and approved the final draft.</p></fn></fn-group><fn-group content-type="other"><title>Data Availability</title><fn id="addinfo-1"><p>The following information was supplied regarding data availability:</p><p>The datasets generated and/or analyzed during the current study are available at GEO: <uri xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE162616">GSE162616</uri>.</p><p>The raw data is available in Github and Zenodo:</p><p>- <ext-link xlink:href="https://github.com/yinuotu356/All-raw-data.git" ext-link-type="uri">https://github.com/yinuotu356/All-raw-data.git</ext-link>
</p><p>- yinuotu356. (2025). yinuotu356/All-raw-data: Updated raw data (v.1.1.1). Zenodo. <ext-link xlink:href="https://doi.org/10.5281/zenodo.14986495" ext-link-type="uri">https://doi.org/10.5281/zenodo.14986495</ext-link>.</p></fn></fn-group></sec><ref-list content-type="authoryear"><title>References</title><ref id="ref-1"><label>Akazawa et&#x000a0;al. (2019)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akazawa</surname><given-names>Y</given-names></name>
<name><surname>Nobuoka</surname><given-names>D</given-names></name>
<name><surname>Takahashi</surname><given-names>M</given-names></name>
<name><surname>Yoshikawa</surname><given-names>T</given-names></name>
<name><surname>Shimomura</surname><given-names>M</given-names></name>
<name><surname>Mizuno</surname><given-names>S</given-names></name>
<name><surname>Fujiwara</surname><given-names>T</given-names></name>
<name><surname>Nakamoto</surname><given-names>Y</given-names></name>
<name><surname>Nakatsura</surname><given-names>T</given-names></name>
</person-group><year iso-8601-date="2019">2019</year><article-title>Higher human lymphocyte antigen class I expression in early-stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes</article-title><source>Cancer Science</source><volume>110</volume><issue>6</issue><fpage>1842</fpage><lpage>1852</lpage><pub-id pub-id-type="doi">10.1111/cas.14022</pub-id><pub-id pub-id-type="pmid">30973665</pub-id>
</element-citation></ref><ref id="ref-2"><label>Cacan (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cacan</surname><given-names>E</given-names></name>
</person-group><year iso-8601-date="2017">2017</year><article-title>Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells</article-title><source>Journal of Chemotherapy (Florence, Italy)</source><volume>29</volume><issue>3</issue><fpage>173</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1080/1120009X.2016.1277007</pub-id><pub-id pub-id-type="pmid">28102109</pub-id>
</element-citation></ref><ref id="ref-3"><label>Cao, Hu &#x00026; Tang (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cao</surname><given-names>Y</given-names></name>
<name><surname>Hu</surname><given-names>L</given-names></name>
<name><surname>Tang</surname><given-names>Y</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Hepatitis B virus X protein-mediated upregulation of miR-221 activates the CXCL12-CXCR4 axis to promote NKT cells in HBV-related hepatocellular carcinoma</article-title><source>Biocell</source><volume>47</volume><issue>7</issue><fpage>1537</fpage><lpage>1548</lpage><pub-id pub-id-type="doi">10.32604/biocell.2023.027205</pub-id></element-citation></ref><ref id="ref-4"><label>Chen et&#x000a0;al. (2025)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Lv</surname><given-names>Q</given-names></name>
<name><surname>Ye</surname><given-names>Y</given-names></name>
<name><surname>Gu</surname><given-names>J</given-names></name>
</person-group><year iso-8601-date="2025">2025</year><article-title>Revealing the role of natural killer cells in ankylosing spondylitis: identifying diagnostic biomarkers and therapeutic targets</article-title><source>Annals of Medicine</source><volume>57</volume><issue>1</issue><elocation-id>2457523</elocation-id><pub-id pub-id-type="doi">10.1080/07853890.2025.2457523</pub-id><pub-id pub-id-type="pmid">39853176</pub-id>
</element-citation></ref><ref id="ref-5"><label>Chen, Lin &#x00026; Luo (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J</given-names></name>
<name><surname>Lin</surname><given-names>A</given-names></name>
<name><surname>Luo</surname><given-names>P</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Advancing pharmaceutical research: a comprehensive review of cutting-edge tools and technologies</article-title><source>Current Pharmaceutical Analysis</source><volume>21</volume><issue>1</issue><fpage>1</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.cpan.2024.11.001</pub-id></element-citation></ref><ref id="ref-6"><label>Chen et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>S</given-names></name>
<name><surname>Tang</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>H</given-names></name>
<name><surname>Tu</surname><given-names>D</given-names></name>
<name><surname>Su</surname><given-names>B</given-names></name>
<name><surname>Peng</surname><given-names>R</given-names></name>
<name><surname>Jin</surname><given-names>S</given-names></name>
<name><surname>Jiang</surname><given-names>G</given-names></name>
<name><surname>Cao</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Bai</surname><given-names>D</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Identifying epithelial-mesenchymal transition-related genes as prognostic biomarkers and therapeutic targets of hepatocellular carcinoma by integrated analysis of single-cell and bulk-RNA sequencing data</article-title><source>Translational Cancer Research</source><volume>13</volume><issue>8</issue><fpage>4257</fpage><lpage>4277</lpage><pub-id pub-id-type="doi">10.21037/tcr-24-521</pub-id><pub-id pub-id-type="pmid">39262476</pub-id>
</element-citation></ref><ref id="ref-7"><label>Chen et&#x000a0;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>H</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Zhou</surname><given-names>L</given-names></name>
<name><surname>Cai</surname><given-names>T</given-names></name>
<name><surname>Liu</surname><given-names>B</given-names></name>
<name><surname>Wang</surname><given-names>L</given-names></name>
<name><surname>Yang</surname><given-names>J</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Identification of CCL19 as a novel immune-related biomarker in diabetic nephropathy</article-title><source>Frontiers in Genetics</source><volume>13</volume><elocation-id>830437</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2022.830437</pub-id><pub-id pub-id-type="pmid">35222545</pub-id>
</element-citation></ref><ref id="ref-8"><label>Chouleur et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chouleur</surname><given-names>T</given-names></name>
<name><surname>Emanuelli</surname><given-names>A</given-names></name>
<name><surname>Souleyreau</surname><given-names>W</given-names></name>
<name><surname>Derieppe</surname><given-names>MA</given-names></name>
<name><surname>Leboucq</surname><given-names>T</given-names></name>
<name><surname>Hardy</surname><given-names>S</given-names></name>
<name><surname>Mathivet</surname><given-names>T</given-names></name>
<name><surname>Tremblay</surname><given-names>ML</given-names></name>
<name><surname>Bikfalvi</surname><given-names>A</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>PTP4A2 promotes glioblastoma progression and macrophage polarization under microenvironmental pressure</article-title><source>Cancer Research Communications</source><volume>4</volume><issue>7</issue><fpage>1702</fpage><lpage>1714</lpage><pub-id pub-id-type="doi">10.1158/2767-9764.CRC-23-0334</pub-id><pub-id pub-id-type="pmid">38904264</pub-id>
</element-citation></ref><ref id="ref-9"><label>Cui et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cui</surname><given-names>Z</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Liu</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Hu</surname><given-names>S</given-names></name>
<name><surname>Zhao</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>G</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Single-cell data revealed exhaustion of characteristic NK cell subpopulations and T cell subpopulations in hepatocellular carcinoma</article-title><source>Aging</source><volume>16</volume><issue>7</issue><fpage>6550</fpage><lpage>6565</lpage><pub-id pub-id-type="doi">10.18632/aging.205723</pub-id><pub-id pub-id-type="pmid">38604154</pub-id>
</element-citation></ref><ref id="ref-10"><label>Dong et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Dong</surname><given-names>B</given-names></name>
<name><surname>Cheng</surname><given-names>R</given-names></name>
<name><surname>Zeng</surname><given-names>H</given-names></name>
<name><surname>Chen</surname><given-names>L</given-names></name>
<name><surname>Zhou</surname><given-names>L</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Identification and validation of co-expressed immune-related gene signature affecting the pattern of immune infiltrating in esophageal cancer</article-title><source>Combinatorial Chemistry &#x00026; High Throughput Screening</source><volume>26</volume><issue>4</issue><fpage>756</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.2174/1386207325666220705105906</pub-id><pub-id pub-id-type="pmid">35959623</pub-id>
</element-citation></ref><ref id="ref-11"><label>Du et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Du</surname><given-names>Y</given-names></name>
<name><surname>Jiang</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Ying</surname><given-names>J</given-names></name>
<name><surname>Yi</surname><given-names>Q</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Integrating single-cell and bulk RNA-seq to construct a metastasis-related model for evaluating immunotherapy and chemotherapy in uveal melanoma</article-title><source>Current Medicinal Chemistry</source><volume>31</volume><issue>42</issue><fpage>7030</fpage><lpage>7042</lpage><pub-id pub-id-type="doi">10.2174/0109298673286355231222054226</pub-id><pub-id pub-id-type="pmid">38173196</pub-id>
</element-citation></ref><ref id="ref-12"><label>Du et&#x000a0;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Du</surname><given-names>Y</given-names></name>
<name><surname>Ma</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>D</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>T</given-names></name>
<name><surname>Bai</surname><given-names>L</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>S</given-names></name>
</person-group><year iso-8601-date="2021">2021</year><article-title>Identification of heterogeneous nuclear ribonucleoprotein as a candidate biomarker for diagnosis and prognosis of hepatocellular carcinoma</article-title><source>Journal of Gastrointestinal Oncology</source><volume>12</volume><issue>5</issue><fpage>2361</fpage><lpage>2376</lpage><pub-id pub-id-type="doi">10.21037/jgo-21-468</pub-id><pub-id pub-id-type="pmid">34790398</pub-id>
</element-citation></ref><ref id="ref-13"><label>Eresen et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Eresen</surname><given-names>A</given-names></name>
<name><surname>Pang</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
<name><surname>Hou</surname><given-names>Q</given-names></name>
<name><surname>Chen</surname><given-names>Z</given-names></name>
<name><surname>Yu</surname><given-names>G</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Yaghmai</surname><given-names>V</given-names></name>
<name><surname>Zhang</surname><given-names>Z</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Sorafenib plus memory like natural killer cell combination therapy in hepatocellular carcinoma</article-title><source>American Journal of Cancer Research</source><volume>14</volume><issue>1</issue><fpage>344</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.62347/PMVN1173</pub-id><pub-id pub-id-type="pmid">38323279</pub-id>
</element-citation></ref><ref id="ref-14"><label>Gao et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>Z</given-names></name>
<name><surname>Dong</surname><given-names>Y</given-names></name>
<name><surname>Yang</surname><given-names>S</given-names></name>
<name><surname>Wu</surname><given-names>B</given-names></name>
<name><surname>Xiao</surname><given-names>M</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Wen</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>L</given-names></name>
<name><surname>Jiang</surname><given-names>H</given-names></name>
<name><surname>Yao</surname><given-names>Y</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>AHSA1 regulates hepatocellular carcinoma progression via the TGF-&#x003b2;/Akt-Cyclin D1/CDK6 pathway</article-title><source>Journal of Hepatocellular Carcinoma</source><volume>10</volume><fpage>2021</fpage><lpage>2036</lpage><pub-id pub-id-type="doi">10.2147/JHC.S407680</pub-id><pub-id pub-id-type="pmid">38022728</pub-id>
</element-citation></ref><ref id="ref-15"><label>Gao et&#x000a0;al. (2017)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>M</given-names></name>
<name><surname>Zheng</surname><given-names>Z</given-names></name>
<name><surname>He</surname><given-names>Y</given-names></name>
<name><surname>Zhu</surname><given-names>Y</given-names></name>
<name><surname>Cheng</surname><given-names>Q</given-names></name>
<name><surname>Rong</surname><given-names>J</given-names></name>
<name><surname>Weng</surname><given-names>H</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Xu</surname><given-names>Y</given-names></name>
<name><surname>Yun</surname><given-names>M</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Ye</surname><given-names>S</given-names></name>
</person-group><year iso-8601-date="2017">2017</year><article-title>Over-expression of protein tyrosine phosphatase 4A2 correlates with tumor progression and poor prognosis in nasopharyngeal carcinoma</article-title><source>Oncotarget</source><volume>8</volume><issue>44</issue><fpage>77527</fpage><lpage>77539</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.20550</pub-id><pub-id pub-id-type="pmid">29100406</pub-id>
</element-citation></ref><ref id="ref-16"><label>Hardy et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hardy</surname><given-names>S</given-names></name>
<name><surname>Zolotarov</surname><given-names>Y</given-names></name>
<name><surname>Coleman</surname><given-names>J</given-names></name>
<name><surname>Roitman</surname><given-names>S</given-names></name>
<name><surname>Khursheed</surname><given-names>H</given-names></name>
<name><surname>Aubry</surname><given-names>I</given-names></name>
<name><surname>Uetani</surname><given-names>N</given-names></name>
<name><surname>Tremblay</surname><given-names>ML</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>PRL-1/2 phosphatases control TRPM7 magnesium-dependent function to regulate cellular bioenergetics</article-title><source>Proceedings of the National Academy of Sciences of the United States of America</source><volume>120</volume><issue>14</issue><elocation-id>e2221083120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2221083120</pub-id><pub-id pub-id-type="pmid">36972446</pub-id>
</element-citation></ref><ref id="ref-17"><label>Hong et&#x000a0;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hong</surname><given-names>G</given-names></name>
<name><surname>Xie</surname><given-names>S</given-names></name>
<name><surname>Guo</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>D</given-names></name>
<name><surname>Ge</surname><given-names>S</given-names></name>
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>Gao</surname><given-names>W</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Progression-free survival of a patient with advanced hepatocellular carcinoma treated with adoptive cell therapy using natural killer cells: a case report</article-title><source>OncoTargets and Therapy</source><volume>15</volume><fpage>255</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.2147/OTT.S344707</pub-id><pub-id pub-id-type="pmid">35313527</pub-id>
</element-citation></ref><ref id="ref-18"><label>Hosseinzadeh et&#x000a0;al. (2019)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosseinzadeh</surname><given-names>F</given-names></name>
<name><surname>Ai</surname><given-names>J</given-names></name>
<name><surname>Ebrahimi-Barough</surname><given-names>S</given-names></name>
<name><surname>Seyhoun</surname><given-names>I</given-names></name>
<name><surname>Hajifathali</surname><given-names>A</given-names></name>
<name><surname>Muhammadnejad</surname><given-names>S</given-names></name>
<name><surname>Hosseinzadeh</surname><given-names>F</given-names></name>
<name><surname>Shadnoush</surname><given-names>M</given-names></name>
<name><surname>Dabiri&#x000a0;Oskouei</surname><given-names>F</given-names></name>
<name><surname>Verdi</surname><given-names>J</given-names></name>
</person-group><year iso-8601-date="2019">2019</year><article-title>Natural killer cell expansion with autologous feeder layer and anti-CD3 antibody for immune cell therapy of hepatocellular carcinoma</article-title><source>Asian Pacific Journal of Cancer Prevention</source><volume>20</volume><issue>12</issue><fpage>3797</fpage><lpage>3803</lpage><pub-id pub-id-type="doi">10.31557/APJCP.2019.20.12.3797</pub-id><pub-id pub-id-type="pmid">31870124</pub-id>
</element-citation></ref><ref id="ref-19"><label>Hosseinzadeh et&#x000a0;al. (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hosseinzadeh</surname><given-names>F</given-names></name>
<name><surname>Verdi</surname><given-names>J</given-names></name>
<name><surname>Ai</surname><given-names>J</given-names></name>
<name><surname>Hajighasemlou</surname><given-names>S</given-names></name>
<name><surname>Seyhoun</surname><given-names>I</given-names></name>
<name><surname>Parvizpour</surname><given-names>F</given-names></name>
<name><surname>Hosseinzadeh</surname><given-names>F</given-names></name>
<name><surname>Iranikhah</surname><given-names>A</given-names></name>
<name><surname>Shirian</surname><given-names>S</given-names></name>
</person-group><year iso-8601-date="2018">2018</year><article-title>Combinational immune-cell therapy of natural killer cells and sorafenib for advanced hepatocellular carcinoma: a review</article-title><source>Cancer Cell International</source><volume>18</volume><fpage>133</fpage><pub-id pub-id-type="doi">10.1186/s12935-018-0624-x</pub-id><pub-id pub-id-type="pmid">30214375</pub-id>
</element-citation></ref><ref id="ref-20"><label>Huang et&#x000a0;al. (2021b)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>Y</given-names></name>
<name><surname>Huang</surname><given-names>X</given-names></name>
<name><surname>Zeng</surname><given-names>J</given-names></name>
<name><surname>Lin</surname><given-names>J</given-names></name>
</person-group><year iso-8601-date="2021">2021b</year><article-title>Knockdown of MUC16 (CA125) enhances the migration and invasion of hepatocellular carcinoma cells</article-title><source>Frontiers in Oncology</source><volume>11</volume><elocation-id>667669</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2021.667669</pub-id><pub-id pub-id-type="pmid">34150633</pub-id>
</element-citation></ref><ref id="ref-21"><label>Huang et&#x000a0;al. (2021a)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huang</surname><given-names>C</given-names></name>
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Sheng</surname><given-names>J</given-names></name>
<name><surname>Wang</surname><given-names>D</given-names></name>
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<name><surname>Qian</surname><given-names>L</given-names></name>
<name><surname>Xie</surname><given-names>L</given-names></name>
<name><surname>Meng</surname><given-names>Z</given-names></name>
</person-group><year iso-8601-date="2021">2021a</year><article-title>Identification and validation of a tumor microenvironment-related gene signature in hepatocellular carcinoma prognosis</article-title><source>Frontiers in Genetics</source><volume>12</volume><elocation-id>717319</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2021.717319</pub-id><pub-id pub-id-type="pmid">34899826</pub-id>
</element-citation></ref><ref id="ref-22"><label>Huo, Wu &#x00026; Zang (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Huo</surname><given-names>J</given-names></name>
<name><surname>Wu</surname><given-names>L</given-names></name>
<name><surname>Zang</surname><given-names>Y</given-names></name>
</person-group><year iso-8601-date="2021">2021</year><article-title>Identification and validation of a novel immune-related signature associated with macrophages and CD8 T cell infiltration predicting overall survival for hepatocellular carcinoma</article-title><source>BMC Medical Genomics</source><volume>14</volume><issue>1</issue><fpage>232</fpage><pub-id pub-id-type="doi">10.1186/s12920-021-01081-z</pub-id><pub-id pub-id-type="pmid">34544391</pub-id>
</element-citation></ref><ref id="ref-23"><label>Ihlow et&#x000a0;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ihlow</surname><given-names>J</given-names></name>
<name><surname>Monj&#x000e9;</surname><given-names>N</given-names></name>
<name><surname>Hoffmann</surname><given-names>I</given-names></name>
<name><surname>Bischoff</surname><given-names>P</given-names></name>
<name><surname>Sinn</surname><given-names>BV</given-names></name>
<name><surname>Schmitt</surname><given-names>WD</given-names></name>
<name><surname>Kunze</surname><given-names>CA</given-names></name>
<name><surname>Darb-Esfahani</surname><given-names>S</given-names></name>
<name><surname>Kulbe</surname><given-names>H</given-names></name>
<name><surname>Braicu</surname><given-names>EI</given-names></name>
<name><surname>Sehouli</surname><given-names>J</given-names></name>
<name><surname>Denkert</surname><given-names>C</given-names></name>
<name><surname>Horst</surname><given-names>D</given-names></name>
<name><surname>Taube</surname><given-names>ET</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Low expression of RGS2 promotes poor prognosis in high-grade serous ovarian cancer</article-title><source>Cancer</source><volume>14</volume><issue>19</issue><fpage>4620</fpage><pub-id pub-id-type="doi">10.3390/cancers14194620</pub-id></element-citation></ref><ref id="ref-24"><label>Jin et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>Y</given-names></name>
<name><surname>Dai</surname><given-names>Y</given-names></name>
<name><surname>Qiao</surname><given-names>O</given-names></name>
<name><surname>Hu</surname><given-names>P</given-names></name>
<name><surname>Han</surname><given-names>J</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>miR-1972 inhibits hepatocellular carcinoma proliferation by targeting GZMH-mediated DNA replication in the cell cycle</article-title><source>The Journal of Pharmacy and Pharmacology</source><volume>77</volume><fpage>142</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1093/jpp/rgae037</pub-id></element-citation></ref><ref id="ref-25"><label>Ke et&#x000a0;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ke</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>C</given-names></name>
<name><surname>Su</surname><given-names>Z</given-names></name>
<name><surname>Lin</surname><given-names>S</given-names></name>
<name><surname>Wu</surname><given-names>G</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Integrated analysis reveals critical ferroptosis regulators and FTL contribute to cancer progression in hepatocellular carcinoma</article-title><source>Frontiers in Genetics</source><volume>13</volume><elocation-id>897683</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2022.897683</pub-id><pub-id pub-id-type="pmid">35651950</pub-id>
</element-citation></ref><ref id="ref-26"><label>Kong &#x00026; Yao (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>DG</given-names></name>
<name><surname>Yao</surname><given-names>FZ</given-names></name>
</person-group><year iso-8601-date="2021">2021</year><article-title>CDC6 is a possible biomarker for hepatocellular carcinoma</article-title><source>International Journal of Clinical and Experimental Pathology</source><volume>14</volume><issue>7</issue><fpage>811</fpage><lpage>818</lpage><pub-id pub-id-type="pmid">34367412</pub-id>
</element-citation></ref><ref id="ref-27"><label>Kuang et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuang</surname><given-names>T</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Chai</surname><given-names>D</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>W</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Construction of a T-cell exhaustion-related gene signature for predicting prognosis and immune response in hepatocellular carcinoma</article-title><source>Aging</source><volume>15</volume><issue>12</issue><fpage>5751</fpage><lpage>5774</lpage><pub-id pub-id-type="doi">10.18632/aging.204830</pub-id><pub-id pub-id-type="pmid">37354485</pub-id>
</element-citation></ref><ref id="ref-28"><label>Lee et&#x000a0;al. (2021a)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>HA</given-names></name>
<name><surname>Chu</surname><given-names>KB</given-names></name>
<name><surname>Moon</surname><given-names>EK</given-names></name>
<name><surname>Quan</surname><given-names>FS</given-names></name>
</person-group><year iso-8601-date="2021">2021a</year><article-title>Histone deacetylase inhibitor-induced CDKN2B and CDKN2D contribute to G2/M cell cycle arrest incurred by oxidative stress in hepatocellular carcinoma cells via forkhead box M1 suppression</article-title><source>Journal of Cancer</source><volume>12</volume><issue>17</issue><fpage>5086</fpage><lpage>5098</lpage><pub-id pub-id-type="doi">10.7150/jca.60027</pub-id><pub-id pub-id-type="pmid">34335925</pub-id>
</element-citation></ref><ref id="ref-29"><label>Lee et&#x000a0;al. (2021b)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>HA</given-names></name>
<name><surname>Goh</surname><given-names>HG</given-names></name>
<name><surname>Lee</surname><given-names>YS</given-names></name>
<name><surname>Jung</surname><given-names>YK</given-names></name>
<name><surname>Kim</surname><given-names>JH</given-names></name>
<name><surname>Yim</surname><given-names>HJ</given-names></name>
<name><surname>Lee</surname><given-names>MG</given-names></name>
<name><surname>An</surname><given-names>H</given-names></name>
<name><surname>Jeen</surname><given-names>YT</given-names></name>
<name><surname>Yeon</surname><given-names>JE</given-names></name>
<name><surname>Byun</surname><given-names>KS</given-names></name>
<name><surname>Seo</surname><given-names>YS</given-names></name>
</person-group><year iso-8601-date="2021">2021b</year><article-title>Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma</article-title><source>BMC Gastroenterology</source><volume>21</volume><issue>1</issue><fpage>258</fpage><pub-id pub-id-type="doi">10.1186/s12876-021-01833-2</pub-id><pub-id pub-id-type="pmid">34118869</pub-id>
</element-citation></ref><ref id="ref-30"><label>Li et&#x000a0;al. (2024a)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Q</given-names></name>
<name><surname>Chu</surname><given-names>Y</given-names></name>
<name><surname>Yao</surname><given-names>Y</given-names></name>
<name><surname>Song</surname><given-names>Q</given-names></name>
</person-group><year iso-8601-date="2024">2024a</year><article-title>A Treg-related riskscore model may improve the prognosis evaluation of colorectal cancer</article-title><source>The Journal of Gene Medicine</source><volume>26</volume><issue>2</issue><elocation-id>e3668</elocation-id><pub-id pub-id-type="doi">10.1002/jgm.3668</pub-id><pub-id pub-id-type="pmid">38342959</pub-id>
</element-citation></ref><ref id="ref-31"><label>Li et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>M</given-names></name>
<name><surname>Huang</surname><given-names>J</given-names></name>
<name><surname>Zhan</surname><given-names>G</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Fang</surname><given-names>C</given-names></name>
<name><surname>Xiang</surname><given-names>B</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>The novel-natural-killer-cell-related gene signature predicts the prognosis and immune status of patients with hepatocellular carcinoma</article-title><source>International Journal of Molecular Sciences</source><volume>24</volume><issue>11</issue><fpage>9587</fpage><pub-id pub-id-type="doi">10.3390/ijms24119587</pub-id><pub-id pub-id-type="pmid">37298537</pub-id>
</element-citation></ref><ref id="ref-32"><label>Li et&#x000a0;al. (2024b)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Lei</surname><given-names>J</given-names></name>
<name><surname>Shi</surname><given-names>Y</given-names></name>
<name><surname>Peng</surname><given-names>Z</given-names></name>
<name><surname>Gong</surname><given-names>M</given-names></name>
<name><surname>Shu</surname><given-names>X</given-names></name>
</person-group><year iso-8601-date="2024">2024b</year><article-title>Developing a RiskScore model based on angiogenesis-related lncRNAs for colon adenocarcinoma prognostic prediction</article-title><source>Current Medicinal Chemistry</source><volume>31</volume><issue>17</issue><fpage>2449</fpage><lpage>2466</lpage><pub-id pub-id-type="doi">10.2174/0109298673277243231108071620</pub-id><pub-id pub-id-type="pmid">37961859</pub-id>
</element-citation></ref><ref id="ref-33"><label>Li &#x00026; Liu (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>W</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>The prognostic and immunotherapeutic significance of AHSA1 in pan-cancer, and its relationship with the proliferation and metastasis of hepatocellular carcinoma</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>845585</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.845585</pub-id><pub-id pub-id-type="pmid">35757728</pub-id>
</element-citation></ref><ref id="ref-34"><label>Li, Liu &#x00026; Qin (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>K</given-names></name>
<name><surname>Liu</surname><given-names>J</given-names></name>
<name><surname>Qin</surname><given-names>X</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Research progress of gut microbiota in hepatocellular carcinoma</article-title><source>Journal of Clinical Laboratory Analysis</source><volume>36</volume><issue>7</issue><elocation-id>e24512</elocation-id><pub-id pub-id-type="doi">10.1002/jcla.24512</pub-id><pub-id pub-id-type="pmid">35719048</pub-id>
</element-citation></ref><ref id="ref-35"><label>Li et&#x000a0;al. (2024c)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Qu</surname><given-names>X</given-names></name>
<name><surname>Li</surname><given-names>S</given-names></name>
<name><surname>Lin</surname><given-names>K</given-names></name>
<name><surname>Yao</surname><given-names>N</given-names></name>
<name><surname>Wang</surname><given-names>N</given-names></name>
<name><surname>Shi</surname><given-names>Y</given-names></name>
</person-group><year iso-8601-date="2024">2024c</year><article-title>Development of a novel CD8(+) T cell-associated signature for prognostic assessment in hepatocellular carcinoma</article-title><source>Cancer Control</source><volume>31</volume><elocation-id>10732748241270583</elocation-id><pub-id pub-id-type="doi">10.1177/10732748241270583</pub-id><pub-id pub-id-type="pmid">39152700</pub-id>
</element-citation></ref><ref id="ref-36"><label>Li et&#x000a0;al. (2010)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Sze</surname><given-names>DM</given-names></name>
<name><surname>Brown</surname><given-names>RD</given-names></name>
<name><surname>Cowley</surname><given-names>MJ</given-names></name>
<name><surname>Kaplan</surname><given-names>W</given-names></name>
<name><surname>Mo</surname><given-names>SL</given-names></name>
<name><surname>Yang</surname><given-names>S</given-names></name>
<name><surname>Aklilu</surname><given-names>E</given-names></name>
<name><surname>Kabani</surname><given-names>K</given-names></name>
<name><surname>Loh</surname><given-names>YS</given-names></name>
<name><surname>Yamagishi</surname><given-names>T</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
<name><surname>Ho</surname><given-names>PJ</given-names></name>
<name><surname>Joshua</surname><given-names>DE</given-names></name>
</person-group><year iso-8601-date="2010">2010</year><article-title>Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenstrom macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy</article-title><source>Blood</source><volume>115</volume><issue>17</issue><fpage>3580</fpage><lpage>3588</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-10-246991</pub-id><pub-id pub-id-type="pmid">20190191</pub-id>
</element-citation></ref><ref id="ref-37"><label>Li et&#x000a0;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Tu</surname><given-names>S</given-names></name>
<name><surname>Zeng</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>C</given-names></name>
<name><surname>Deng</surname><given-names>T</given-names></name>
<name><surname>Luo</surname><given-names>W</given-names></name>
<name><surname>Lian</surname><given-names>L</given-names></name>
<name><surname>Chen</surname><given-names>L</given-names></name>
<name><surname>Xiong</surname><given-names>X</given-names></name>
<name><surname>Yan</surname><given-names>X</given-names></name>
</person-group><year iso-8601-date="2020">2020</year><article-title>KLF2 inhibits TGF-&#x003b2;-mediated cancer cell motility in hepatocellular carcinoma</article-title><source>Acta Biochimica Et Biophysica Sinica</source><volume>52</volume><issue>5</issue><fpage>485</fpage><lpage>494</lpage><pub-id pub-id-type="doi">10.1093/abbs/gmaa024</pub-id><pub-id pub-id-type="pmid">32318691</pub-id>
</element-citation></ref><ref id="ref-38"><label>Li et&#x000a0;al. (2024d)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>Y-N</given-names></name>
<name><surname>Xiu</surname><given-names>Y-H</given-names></name>
<name><surname>Tang</surname><given-names>Y-J</given-names></name>
<name><surname>Cao</surname><given-names>J-L</given-names></name>
<name><surname>Hou</surname><given-names>W-S</given-names></name>
<name><surname>Wang</surname><given-names>A-Q</given-names></name>
<name><surname>Li</surname><given-names>T-Z</given-names></name>
<name><surname>Jin</surname><given-names>C-H</given-names></name>
</person-group><year iso-8601-date="2024">2024d</year><article-title>Sciadopitysin exerts anticancer effects on HepG2 hepatocellular carcinoma cells by regulating reactive oxygen species-mediated signaling pathways</article-title><source>Biocell</source><volume>48</volume><issue>7</issue><fpage>1055</fpage><lpage>1069</lpage><pub-id pub-id-type="doi">10.32604/biocell.2024.050515</pub-id></element-citation></ref><ref id="ref-39"><label>Lian et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lian</surname><given-names>W</given-names></name>
<name><surname>Xiang</surname><given-names>P</given-names></name>
<name><surname>Ye</surname><given-names>C</given-names></name>
<name><surname>Xiong</surname><given-names>J</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Single-cell RNA sequencing analysis reveals the role of cancerassociated fibroblasts in skin melanoma</article-title><source>Current Medicinal Chemistry</source><volume>31</volume><issue>42</issue><fpage>7015</fpage><lpage>7029</lpage><pub-id pub-id-type="doi">10.2174/0109298673282799231211113347</pub-id><pub-id pub-id-type="pmid">38173195</pub-id>
</element-citation></ref><ref id="ref-40"><label>Lin et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>Z</given-names></name>
<name><surname>He</surname><given-names>Y</given-names></name>
<name><surname>Wu</surname><given-names>Z</given-names></name>
<name><surname>Yuan</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>X</given-names></name>
<name><surname>Luo</surname><given-names>W</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Comprehensive analysis of copper-metabolism-related genes about prognosis and immune microenvironment in osteosarcoma</article-title><source>Scientific Reports</source><volume>13</volume><issue>1</issue><fpage>15059</fpage><pub-id pub-id-type="doi">10.1038/s41598-023-42053-w</pub-id><pub-id pub-id-type="pmid">37700003</pub-id>
</element-citation></ref><ref id="ref-41"><label>Lin et&#x000a0;al. (2019)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lin</surname><given-names>J</given-names></name>
<name><surname>Tan</surname><given-names>H</given-names></name>
<name><surname>Nie</surname><given-names>Y</given-names></name>
<name><surname>Wu</surname><given-names>D</given-names></name>
<name><surname>Zheng</surname><given-names>W</given-names></name>
<name><surname>Lin</surname><given-names>W</given-names></name>
<name><surname>Zhu</surname><given-names>Z</given-names></name>
<name><surname>Yang</surname><given-names>B</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Chen</surname><given-names>T</given-names></name>
</person-group><year iso-8601-date="2019">2019</year><article-title>Kr&#x000fc;ppel-like factor 2 inhibits hepatocarcinogenesis through negative regulation of the Hedgehog pathway</article-title><source>Cancer Science</source><volume>110</volume><issue>4</issue><fpage>1220</fpage><lpage>1231</lpage><pub-id pub-id-type="doi">10.1111/cas.13961</pub-id><pub-id pub-id-type="pmid">30719823</pub-id>
</element-citation></ref><ref id="ref-42"><label>Liu et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Lei</surname><given-names>X</given-names></name>
<name><surname>Huang</surname><given-names>S</given-names></name>
<name><surname>Yang</surname><given-names>X</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Current perspectives of immunotherapy for hepatocellular carcinoma</article-title><source>Combinatorial Chemistry &#x00026; High Throughput Screening</source><volume>28</volume><fpage>185</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.2174/0113862073255266231025111125</pub-id></element-citation></ref><ref id="ref-43"><label>Liu et&#x000a0;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>Z</given-names></name>
<name><surname>Qi</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name>
<name><surname>Zhang</surname><given-names>Q</given-names></name>
<name><surname>Wu</surname><given-names>Z</given-names></name>
<name><surname>Wu</surname><given-names>W</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Risk model of hepatocellular carcinoma based on cuproptosis-related genes</article-title><source>Frontiers in Genetics</source><volume>13</volume><elocation-id>1000652</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2022.1000652</pub-id><pub-id pub-id-type="pmid">36186455</pub-id>
</element-citation></ref><ref id="ref-44"><label>Lu et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>H</given-names></name>
<name><surname>Xu</surname><given-names>Z</given-names></name>
<name><surname>Shao</surname><given-names>L</given-names></name>
<name><surname>Li</surname><given-names>P</given-names></name>
<name><surname>Xia</surname><given-names>Y</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>High infiltration of immune cells with lower immune activity mediated the heterogeneity of gastric adenocarcinoma and promoted metastasis</article-title><source>Heliyon</source><volume>10</volume><issue>17</issue><elocation-id>e37092</elocation-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e37092</pub-id><pub-id pub-id-type="pmid">39319155</pub-id>
</element-citation></ref><ref id="ref-45"><label>Luo et&#x000a0;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luo</surname><given-names>D</given-names></name>
<name><surname>Liao</surname><given-names>S</given-names></name>
<name><surname>Liu</surname><given-names>Y</given-names></name>
<name><surname>Lin</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>Y</given-names></name>
<name><surname>Liao</surname><given-names>X</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Holliday cross-recognition protein HJURP: association with the tumor microenvironment in hepatocellular carcinoma and with patient prognosis</article-title><source>Pathology Oncology Research: POR</source><volume>28</volume><elocation-id>1610506</elocation-id><pub-id pub-id-type="doi">10.3389/pore.2022.1610506</pub-id><pub-id pub-id-type="pmid">35783358</pub-id>
</element-citation></ref><ref id="ref-46"><label>Maeser, Gruener &#x00026; Huang (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maeser</surname><given-names>D</given-names></name>
<name><surname>Gruener</surname><given-names>RF</given-names></name>
<name><surname>Huang</surname><given-names>RS</given-names></name>
</person-group><year iso-8601-date="2021">2021</year><article-title>oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data</article-title><source>Briefings in Bioinformatics</source><volume>22</volume><issue>6</issue><elocation-id>bbab260</elocation-id><pub-id pub-id-type="doi">10.1093/bib/bbab260</pub-id><pub-id pub-id-type="pmid">34260682</pub-id>
</element-citation></ref><ref id="ref-47"><label>Poulet et&#x000a0;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Poulet</surname><given-names>M</given-names></name>
<name><surname>Sirois</surname><given-names>J</given-names></name>
<name><surname>Boy&#x000e9;</surname><given-names>K</given-names></name>
<name><surname>Uetani</surname><given-names>N</given-names></name>
<name><surname>Hardy</surname><given-names>S</given-names></name>
<name><surname>Daubon</surname><given-names>T</given-names></name>
<name><surname>Dubrac</surname><given-names>A</given-names></name>
<name><surname>Tremblay</surname><given-names>ML</given-names></name>
<name><surname>Bikfalvi</surname><given-names>A</given-names></name>
</person-group><year iso-8601-date="2020">2020</year><article-title>PRL-2 phosphatase is required for vascular morphogenesis and angiogenic signaling</article-title><source>Communications Biology</source><volume>3</volume><issue>1</issue><fpage>603</fpage><pub-id pub-id-type="doi">10.1038/s42003-020-01343-z</pub-id><pub-id pub-id-type="pmid">33097786</pub-id>
</element-citation></ref><ref id="ref-48"><label>Sensi et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sensi</surname><given-names>B</given-names></name>
<name><surname>Angelico</surname><given-names>R</given-names></name>
<name><surname>Toti</surname><given-names>L</given-names></name>
<name><surname>Conte</surname><given-names>LE</given-names></name>
<name><surname>Coppola</surname><given-names>A</given-names></name>
<name><surname>Tisone</surname><given-names>G</given-names></name>
<name><surname>Manzia</surname><given-names>TM</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Mechanism, potential, and concerns of immunotherapy for hepatocellular carcinoma and liver transplantation</article-title><source>Current Molecular Pharmacology</source><volume>17</volume><elocation-id>e18761429310703</elocation-id><pub-id pub-id-type="doi">10.2174/0118761429310703240823045808</pub-id><pub-id pub-id-type="pmid">39225204</pub-id>
</element-citation></ref><ref id="ref-49"><label>Shin et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shin</surname><given-names>SK</given-names></name>
<name><surname>Oh</surname><given-names>S</given-names></name>
<name><surname>Chun</surname><given-names>SK</given-names></name>
<name><surname>Ahn</surname><given-names>MJ</given-names></name>
<name><surname>Lee</surname><given-names>SM</given-names></name>
<name><surname>Kim</surname><given-names>K</given-names></name>
<name><surname>Kang</surname><given-names>H</given-names></name>
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Shin</surname><given-names>SP</given-names></name>
<name><surname>Lee</surname><given-names>J</given-names></name>
<name><surname>Jung</surname><given-names>YK</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Immune signature and therapeutic approach of natural killer cell in chronic liver disease and hepatocellular carcinoma</article-title><source>Journal of Gastroenterology and Hepatology</source><volume>39</volume><issue>9</issue><fpage>1717</fpage><lpage>1727</lpage><pub-id pub-id-type="doi">10.1111/jgh.16584</pub-id><pub-id pub-id-type="pmid">38800890</pub-id>
</element-citation></ref><ref id="ref-50"><label>Song et&#x000a0;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Song</surname><given-names>F</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Pan</surname><given-names>Z</given-names></name>
<name><surname>Zhang</surname><given-names>Q</given-names></name>
<name><surname>Lu</surname><given-names>X</given-names></name>
<name><surname>Huang</surname><given-names>P</given-names></name>
</person-group><year iso-8601-date="2021">2021</year><article-title>Resveratrol inhibits the migration, invasion and epithelial-mesenchymal transition in liver cancer cells through up- MiR-186-5p expression</article-title><source>Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences</source><volume>50</volume><issue>5</issue><fpage>582</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.3724/zdxbyxb-2021-0197</pub-id><pub-id pub-id-type="pmid">34986537</pub-id>
</element-citation></ref><ref id="ref-51"><label>Sun et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>L</given-names></name>
<name><surname>Liu</surname><given-names>Z</given-names></name>
<name><surname>Wu</surname><given-names>Z</given-names></name>
<name><surname>Ning</surname><given-names>K</given-names></name>
<name><surname>Hu</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>Z</given-names></name>
<name><surname>Wu</surname><given-names>Z</given-names></name>
<name><surname>Yin</surname><given-names>X</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Molecular subtype identification and signature construction based on Golgi apparatus-related genes for better prediction prognosis and immunotherapy response in hepatocellular carcinoma</article-title><source>Frontiers in Immunology</source><volume>14</volume><elocation-id>1113455</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2023.1113455</pub-id><pub-id pub-id-type="pmid">37051238</pub-id>
</element-citation></ref><ref id="ref-52"><label>Sung &#x00026; Jang (2018)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sung</surname><given-names>PS</given-names></name>
<name><surname>Jang</surname><given-names>JW</given-names></name>
</person-group><year iso-8601-date="2018">2018</year><article-title>Natural killer cell dysfunction in hepatocellular carcinoma: pathogenesis and clinical implications</article-title><source>International Journal of Molecular Sciences</source><volume>19</volume><issue>11</issue><fpage>3648</fpage><pub-id pub-id-type="doi">10.3390/ijms19113648</pub-id><pub-id pub-id-type="pmid">30463262</pub-id>
</element-citation></ref><ref id="ref-53"><label>Tao et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tao</surname><given-names>L</given-names></name>
<name><surname>Jiang</surname><given-names>W</given-names></name>
<name><surname>Li</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Tian</surname><given-names>Z</given-names></name>
<name><surname>Yang</surname><given-names>K</given-names></name>
<name><surname>Zhu</surname><given-names>Y</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Single-cell RNA sequencing reveals that an imbalance in monocyte subsets rather than changes in gene expression patterns is a feature of postmenopausal osteoporosis</article-title><source>Journal of Bone and Mineral Research</source><volume>39</volume><issue>7</issue><fpage>980</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1093/jbmr/zjae065</pub-id><pub-id pub-id-type="pmid">38652170</pub-id>
</element-citation></ref><ref id="ref-54"><label>Wang et&#x000a0;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>H</given-names></name>
<name><surname>Wang</surname><given-names>H</given-names></name>
<name><surname>Cui</surname><given-names>W</given-names></name>
<name><surname>Zhang</surname><given-names>Q</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>Q</given-names></name>
</person-group><year iso-8601-date="2021">2021</year><article-title>Enhanced expression of miR-889 forecasts an unfavorable prognosis and facilitates cell progression in hepatocellular carcinoma</article-title><source>Diagnostic Pathology</source><volume>16</volume><issue>1</issue><fpage>51</fpage><pub-id pub-id-type="doi">10.1186/s13000-021-01111-5</pub-id><pub-id pub-id-type="pmid">34116691</pub-id>
</element-citation></ref><ref id="ref-55"><label>Wang et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Yu</surname><given-names>J</given-names></name>
<name><surname>Wen</surname><given-names>H</given-names></name>
<name><surname>Yan</surname><given-names>J</given-names></name>
<name><surname>Peng</surname><given-names>K</given-names></name>
<name><surname>Zhou</surname><given-names>H</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Antioxidative stress protein SRXN1 can be used as a radiotherapy prognostic marker for prostate cancer</article-title><source>BMC Urology</source><volume>23</volume><issue>1</issue><fpage>148</fpage><pub-id pub-id-type="doi">10.1186/s12894-023-01319-1</pub-id><pub-id pub-id-type="pmid">37726767</pub-id>
</element-citation></ref><ref id="ref-56"><label>Wu et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>Y</given-names></name>
<name><surname>Chen</surname><given-names>J</given-names></name>
<name><surname>Zhu</surname><given-names>R</given-names></name>
<name><surname>Huang</surname><given-names>G</given-names></name>
<name><surname>Zeng</surname><given-names>J</given-names></name>
<name><surname>Yu</surname><given-names>H</given-names></name>
<name><surname>He</surname><given-names>Z</given-names></name>
<name><surname>Han</surname><given-names>C</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Integrating TCGA and single-cell sequencing data for hepatocellular carcinoma: a novel glycosylation (GLY)/tumor microenvironment (TME) classifier to predict prognosis and immunotherapy response</article-title><source>Metabolites</source><volume>14</volume><issue>1</issue><fpage>51</fpage><pub-id pub-id-type="doi">10.3390/metabo14010051</pub-id><pub-id pub-id-type="pmid">38248854</pub-id>
</element-citation></ref><ref id="ref-57"><label>Wu et&#x000a0;al. (2022)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wu</surname><given-names>X</given-names></name>
<name><surname>Wan</surname><given-names>R</given-names></name>
<name><surname>Ren</surname><given-names>L</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Ding</surname><given-names>Y</given-names></name>
<name><surname>Wang</surname><given-names>W</given-names></name>
</person-group><year iso-8601-date="2022">2022</year><article-title>Circulating MicroRNA panel as a diagnostic marker for hepatocellular carcinoma</article-title><source>The Turkish Journal of Gastroenterology</source><volume>33</volume><issue>10</issue><fpage>844</fpage><lpage>851</lpage><pub-id pub-id-type="doi">10.5152/tjg.2022.21183</pub-id><pub-id pub-id-type="pmid">35943150</pub-id>
</element-citation></ref><ref id="ref-58"><label>Xiao et&#x000a0;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>Z</given-names></name>
<name><surname>Hu</surname><given-names>L</given-names></name>
<name><surname>Yang</surname><given-names>L</given-names></name>
<name><surname>Wang</surname><given-names>S</given-names></name>
<name><surname>Gao</surname><given-names>Y</given-names></name>
<name><surname>Zhu</surname><given-names>Q</given-names></name>
<name><surname>Yang</surname><given-names>G</given-names></name>
<name><surname>Huang</surname><given-names>D</given-names></name>
<name><surname>Xu</surname><given-names>Q</given-names></name>
</person-group><year iso-8601-date="2020">2020</year><article-title>TGF&#x003b2;2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer</article-title><source>Journal of Cellular and Molecular Medicine</source><volume>24</volume><issue>13</issue><fpage>7151</fpage><lpage>7162</lpage><pub-id pub-id-type="doi">10.1111/jcmm.15164</pub-id><pub-id pub-id-type="pmid">32530106</pub-id>
</element-citation></ref><ref id="ref-59"><label>Xu et&#x000a0;al. (2020a)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>D</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Zhou</surname><given-names>K</given-names></name>
<name><surname>Wu</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>JC</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Chen</surname><given-names>L</given-names></name>
<name><surname>Zheng</surname><given-names>J</given-names></name>
</person-group><year iso-8601-date="2020">2020a</year><article-title>Identification of immune subtypes and prognosis of hepatocellular carcinoma based on immune checkpoint gene expression profile</article-title><source>Biomedicine &#x00026; Pharmacotherapy = Biomedecine &#x00026; Pharmacotherapie</source><volume>126</volume><elocation-id>109903</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2020.109903</pub-id><pub-id pub-id-type="pmid">32113055</pub-id>
</element-citation></ref><ref id="ref-60"><label>Xu et&#x000a0;al. (2020b)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xu</surname><given-names>J</given-names></name>
<name><surname>Yan</surname><given-names>B</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Zhou</surname><given-names>L</given-names></name>
<name><surname>Zhang</surname><given-names>J</given-names></name>
<name><surname>Yu</surname><given-names>W</given-names></name>
<name><surname>Dong</surname><given-names>X</given-names></name>
<name><surname>Yao</surname><given-names>L</given-names></name>
<name><surname>Shan</surname><given-names>L</given-names></name>
</person-group><year iso-8601-date="2020">2020b</year><article-title>Theabrownin induces apoptosis and tumor inhibition of hepatocellular carcinoma Huh7 cells through ASK1-JNK-c-Jun pathway</article-title><source>OncoTargets and Therapy</source><volume>13</volume><fpage>8977</fpage><lpage>8987</lpage><pub-id pub-id-type="doi">10.2147/OTT.S254693</pub-id><pub-id pub-id-type="pmid">32982289</pub-id>
</element-citation></ref><ref id="ref-61"><label>Yang et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>She</surname><given-names>S</given-names></name>
<name><surname>Ren</surname><given-names>L</given-names></name>
<name><surname>Zhao</surname><given-names>B</given-names></name>
<name><surname>Chen</surname><given-names>D</given-names></name>
<name><surname>Chen</surname><given-names>H</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Prognosis and therapeutic benefits prediction based on NK cell marker genes through single-cell RNA-seq with integrated bulk RNA-seq analysis for hepatocellular carcinoma</article-title><source>Frontiers in Oncology</source><volume>13</volume><elocation-id>1208165</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2023.1208165</pub-id><pub-id pub-id-type="pmid">37554171</pub-id>
</element-citation></ref><ref id="ref-62"><label>Zecca et&#x000a0;al. (2020)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zecca</surname><given-names>A</given-names></name>
<name><surname>Barili</surname><given-names>V</given-names></name>
<name><surname>Canetti</surname><given-names>D</given-names></name>
<name><surname>Regina</surname><given-names>V</given-names></name>
<name><surname>Olivani</surname><given-names>A</given-names></name>
<name><surname>Carone</surname><given-names>C</given-names></name>
<name><surname>Capizzuto</surname><given-names>V</given-names></name>
<name><surname>Zerbato</surname><given-names>B</given-names></name>
<name><surname>Trenti</surname><given-names>T</given-names></name>
<name><surname>Valle</surname><given-names>RDalla</given-names></name>
<name><surname>Ferrari</surname><given-names>C</given-names></name>
<name><surname>Cariani</surname><given-names>E</given-names></name>
<name><surname>Missale</surname><given-names>G</given-names></name>
</person-group><year iso-8601-date="2020">2020</year><article-title>Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma</article-title><source>Cancer Immunology, Immunotherapy: CII</source><volume>69</volume><issue>8</issue><fpage>1589</fpage><lpage>1603</lpage><pub-id pub-id-type="doi">10.1007/s00262-020-02561-4</pub-id><pub-id pub-id-type="pmid">32307580</pub-id>
</element-citation></ref><ref id="ref-63"><label>Zeng &#x00026; Chen (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zeng</surname><given-names>L</given-names></name>
<name><surname>Chen</surname><given-names>Z</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Screening of genes characteristic of pancreatic cancer by LASSO regression combined with support vector machine and recursive feature elimination, and immune correlation analysis</article-title><source>The Journal of International Medical Research</source><volume>52</volume><issue>3</issue><elocation-id>3000605241233160</elocation-id><pub-id pub-id-type="doi">10.1177/03000605241233160</pub-id><pub-id pub-id-type="pmid">38456653</pub-id>
</element-citation></ref><ref id="ref-64"><label>Zhang et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>Y</given-names></name>
<name><surname>Pan</surname><given-names>C</given-names></name>
<name><surname>Wang</surname><given-names>W</given-names></name>
<name><surname>Yu</surname><given-names>Y</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>HPV-driven heterogeneity in cervical cancer: study on the role of epithelial cells and myofibroblasts in the tumor progression based on single-cell RNA sequencing analysis</article-title><source>PeerJ</source><volume>12</volume><elocation-id>e18158</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.18158</pub-id><pub-id pub-id-type="pmid">39346086</pub-id>
</element-citation></ref><ref id="ref-65"><label>Zhao et&#x000a0;al. (2019)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>Y</given-names></name>
<name><surname>You</surname><given-names>S</given-names></name>
<name><surname>Yu</surname><given-names>YQ</given-names></name>
<name><surname>Zhang</surname><given-names>S</given-names></name>
<name><surname>Li</surname><given-names>PT</given-names></name>
<name><surname>Ye</surname><given-names>YH</given-names></name>
<name><surname>Zhao</surname><given-names>WX</given-names></name>
<name><surname>Li</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>Q</given-names></name>
<name><surname>Jiao</surname><given-names>H</given-names></name>
<name><surname>Chi</surname><given-names>XQ</given-names></name>
<name><surname>Wang</surname><given-names>XM</given-names></name>
</person-group><year iso-8601-date="2019">2019</year><article-title>Decreased nuclear expression of FTO in human primary hepatocellular carcinoma is associated with poor prognosis</article-title><source>International Journal of Clinical and Experimental Pathology</source><volume>12</volume><issue>9</issue><fpage>3376</fpage><lpage>3383</lpage><pub-id pub-id-type="pmid">31934180</pub-id>
</element-citation></ref><ref id="ref-66"><label>Zhou et&#x000a0;al. (2024)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>Y</given-names></name>
<name><surname>Gu</surname><given-names>J</given-names></name>
<name><surname>Yu</surname><given-names>H</given-names></name>
<name><surname>Chen</surname><given-names>F</given-names></name>
<name><surname>Long</surname><given-names>C</given-names></name>
<name><surname>Maihemuti</surname><given-names>M</given-names></name>
<name><surname>Chen</surname><given-names>T</given-names></name>
<name><surname>Zhang</surname><given-names>W</given-names></name>
</person-group><year iso-8601-date="2024">2024</year><article-title>Screening and identification of ESR1 as a target of icaritin in hepatocellular carcinoma: evidence from bibliometrics and bioinformatic analysis</article-title><source>Current Molecular Pharmacology</source><volume>17</volume><comment>Epub ahead of print 18 April 2025</comment><pub-id pub-id-type="doi">10.2174/0118761429260902230925044009</pub-id></element-citation></ref><ref id="ref-67"><label>Zhou et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>L</given-names></name>
<name><surname>Lin</surname><given-names>X</given-names></name>
<name><surname>Zhu</surname><given-names>J</given-names></name>
<name><surname>Zhang</surname><given-names>L</given-names></name>
<name><surname>Chen</surname><given-names>S</given-names></name>
<name><surname>Yang</surname><given-names>H</given-names></name>
<name><surname>Jia</surname><given-names>L</given-names></name>
<name><surname>Chen</surname><given-names>B</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>NEDD8-conjugating enzyme E2s: critical targets for cancer therapy</article-title><source>Cell Death Discovery</source><volume>9</volume><fpage>23</fpage><pub-id pub-id-type="doi">10.1038/s41420-023-01337-w</pub-id><pub-id pub-id-type="pmid">36690633</pub-id>
</element-citation></ref><ref id="ref-68"><label>Zhou et&#x000a0;al. (2020b)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>PC</given-names></name>
<name><surname>Sun</surname><given-names>LQ</given-names></name>
<name><surname>Shao</surname><given-names>L</given-names></name>
<name><surname>Yi</surname><given-names>LZ</given-names></name>
<name><surname>Li</surname><given-names>N</given-names></name>
<name><surname>Fan</surname><given-names>XG</given-names></name>
</person-group><year iso-8601-date="2020">2020b</year><article-title>Establishment of a pattern recognition metabolomics model for the diagnosis of hepatocellular carcinoma</article-title><source>World Journal of Gastroenterology</source><volume>26</volume><issue>31</issue><fpage>4607</fpage><lpage>4623</lpage><pub-id pub-id-type="doi">10.3748/wjg.v26.i31.4607</pub-id><pub-id pub-id-type="pmid">32884220</pub-id>
</element-citation></ref><ref id="ref-69"><label>Zhou et&#x000a0;al. (2020a)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>L</given-names></name>
<name><surname>Zhu</surname><given-names>J</given-names></name>
<name><surname>Chen</surname><given-names>W</given-names></name>
<name><surname>Jiang</surname><given-names>Y</given-names></name>
<name><surname>Hu</surname><given-names>T</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Ye</surname><given-names>X</given-names></name>
<name><surname>Zhan</surname><given-names>M</given-names></name>
<name><surname>Ji</surname><given-names>C</given-names></name>
<name><surname>Xu</surname><given-names>Z</given-names></name>
<name><surname>Wang</surname><given-names>X</given-names></name>
<name><surname>Gu</surname><given-names>Y</given-names></name>
<name><surname>Jia</surname><given-names>L</given-names></name>
</person-group><year iso-8601-date="2020">2020a</year><article-title>Induction of NEDD8-conjugating enzyme E2 UBE2F by platinum protects lung cancer cells from apoptosis and confers to platinum-insensitivity</article-title><source>Cell Death &#x00026; Disease</source><volume>11</volume><issue>11</issue><fpage>975</fpage><pub-id pub-id-type="doi">10.1038/s41419-020-03184-4</pub-id><pub-id pub-id-type="pmid">33184273</pub-id>
</element-citation></ref><ref id="ref-70"><label>Zhu et&#x000a0;al. (2021)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>HY</given-names></name>
<name><surname>Gao</surname><given-names>YJ</given-names></name>
<name><surname>Wang</surname><given-names>Y</given-names></name>
<name><surname>Liang</surname><given-names>C</given-names></name>
<name><surname>Zhang</surname><given-names>ZX</given-names></name>
<name><surname>Chen</surname><given-names>Y</given-names></name>
</person-group><year iso-8601-date="2021">2021</year><article-title>LncRNA CRNDE promotes the progression and angiogenesis of pancreatic cancer via miR-451a/CDKN2D axis</article-title><source>Translational Oncology</source><volume>14</volume><issue>7</issue><elocation-id>101088</elocation-id><pub-id pub-id-type="doi">10.1016/j.tranon.2021.101088</pub-id><pub-id pub-id-type="pmid">33882369</pub-id>
</element-citation></ref><ref id="ref-71"><label>Zhu et&#x000a0;al. (2023b)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>P</given-names></name>
<name><surname>Pei</surname><given-names>Y</given-names></name>
<name><surname>Yu</surname><given-names>J</given-names></name>
<name><surname>Ding</surname><given-names>W</given-names></name>
<name><surname>Yang</surname><given-names>Y</given-names></name>
<name><surname>Liu</surname><given-names>F</given-names></name>
<name><surname>Liu</surname><given-names>L</given-names></name>
<name><surname>Huang</surname><given-names>J</given-names></name>
<name><surname>Yuan</surname><given-names>S</given-names></name>
<name><surname>Wang</surname><given-names>Z</given-names></name>
<name><surname>Gu</surname><given-names>F</given-names></name>
<name><surname>Pan</surname><given-names>Z</given-names></name>
<name><surname>Chen</surname><given-names>J</given-names></name>
<name><surname>Qiu</surname><given-names>J</given-names></name>
<name><surname>Liu</surname><given-names>H</given-names></name>
</person-group><year iso-8601-date="2023">2023b</year><article-title>High-throughput sequencing approach for the identification of lncRNA biomarkers in hepatocellular carcinoma and revealing the effect of ZFAS1/miR-150-5p on hepatocellular carcinoma progression</article-title><source>PeerJ</source><volume>11</volume><elocation-id>e14891</elocation-id><pub-id pub-id-type="doi">10.7717/peerj.14891</pub-id><pub-id pub-id-type="pmid">36855431</pub-id>
</element-citation></ref><ref id="ref-72"><label>Zhu et&#x000a0;al. (2023a)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>J</given-names></name>
<name><surname>Xu</surname><given-names>X</given-names></name>
<name><surname>Jiang</surname><given-names>M</given-names></name>
<name><surname>Yang</surname><given-names>F</given-names></name>
<name><surname>Mei</surname><given-names>Y</given-names></name>
<name><surname>Zhang</surname><given-names>X</given-names></name>
</person-group><year iso-8601-date="2023">2023a</year><article-title>Comprehensive characterization of ferroptosis in hepatocellular carcinoma revealing the association with prognosis and tumor immune microenvironment</article-title><source>Frontiers in Oncology</source><volume>13</volume><elocation-id>1145380</elocation-id><pub-id pub-id-type="doi">10.3389/fonc.2023.1145380</pub-id><pub-id pub-id-type="pmid">37051544</pub-id>
</element-citation></ref><ref id="ref-73"><label>Zulibiya et&#x000a0;al. (2023)</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zulibiya</surname><given-names>A</given-names></name>
<name><surname>Wen</surname><given-names>J</given-names></name>
<name><surname>Yu</surname><given-names>H</given-names></name>
<name><surname>Chen</surname><given-names>X</given-names></name>
<name><surname>Xu</surname><given-names>L</given-names></name>
<name><surname>Ma</surname><given-names>X</given-names></name>
<name><surname>Zhang</surname><given-names>B</given-names></name>
</person-group><year iso-8601-date="2023">2023</year><article-title>Single-cell RNA sequencing reveals potential for endothelial-to-mesenchymal transition in tetralogy of fallot</article-title><source>Congenital Heart Disease</source><volume>18</volume><issue>6</issue><fpage>611</fpage><lpage>625</lpage><pub-id pub-id-type="doi">10.32604/chd.2023.047689</pub-id></element-citation></ref></ref-list></back></article>